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Nanotechnology is heavily accelerating the pace of functional materials development.
Benefits of nano-engineered materials can be found in several applications ranging
from informatics, automotive, sensing and medicine. In the field of drug delivery
(DD) the nanostructured materials are increasingly investigated as drug delivery
systems (DDSs), i.e. as vehicles designed to transport and deliver the pharmaceutical
compounds to the target place, while protecting them from degradation. The
development of DDSs is encouraged by the fact that they overcome some of the main
issues in DD: they can be designed to release the drugs in a rate-controlled manner,
under specific stimuli and only at the desired place; furthermore, they increase the
active ingredients water solubility. The low solubility of a huge number of drugs
decreases their bioavailability (defined as the extent and rate at which the active
moiety enters the systemic circulation, thereby accessing the site of action) and
results in an increase of the medicament dose.
The focus of this work is to understand the physical and chemical processes gov-
erning the interactions of hydrophobic molecules with both inorganic and organic
nanostructured carriers. I investigate porous silicon (Psi) and nanocellulose (NC)
hydrogels as vehicles for β-carotene (BC) and clofazimine (CFZ).
Psi is fabricated from crystalline silicon (c-Si) through an electrochemical etching
in hydrofluoric (HF) acid solutions. The silicon corrosion occurs along preferred
directions and pores with well defined shapes are formed; both pores dimension and
shape can be tuned by changing the experimental parameters. The easy fabrication
and the great flexibility in the porous morphology that can be obtained, make Psi a
suitable and versatile material for various applications. Concerning DD, Psi is heavily
studied since its porosity can reach 80% and its surface/volume ratio is very high (up
to several hundreds of m2/cm3), thus it allows high drug-loading capacity; nowadays
there are already private companies (e.g. pSiMedica Ltd. (UK) and pSivida (USA))
dedicated to manufacture and market DDSs based on Psi. Moreover the fact that
it is opaque might encourage its use to protect light-sensitive drugs. Another great
advantage is the possibility to individually address the internal pore surface and the
external with different functionalization strategies on the same sample (the interior
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surface is optimised to the loaded cargo, while the external to hide the particle to
the immune system) [1–3]. Once Psi is reduced to nanosize, it becomes an efficient
photoluminescent material, thus it can be used as fluorescent tag, too.
Cellulose is the most abundant and renewable polysaccharide in nature and it
is characterized by a hierarchical structure based on nanometric fibrils that are
extracted from native cellulose by deconstruction reactions. From these nano-sized
elements (the so called nanocellulose (NC)) various nanomaterials (such as film,
hydrogels and aerogels) can be prepared. Hydrogels are very promising DDSs, since
they are three dimensional, hydrophilic networks capable of trapping large amount
of water. For this reason they are widely exploited as carriers for hydrophilic drugs
and there are only few results about their use for hydrophobic molecules.
In this work I exploit the co-loading of drug and surfactant to increase the lipophilic
compounds water solubility. Literature reports contradicting results regarding the
surfactant class that provides the highest solubilization capacity for poorly water
soluble molecules [4–6]. Moreover, the facts that ionic surfactants could hinder the
NC hydrogels formation acting as cross-linkers and that non-ionic surfactants are
more effective in solubilizing CFZ in aqueous environment [7, 8], lead me to use the
non-ionic ones. Among them I choose Tween-20 (TW20) and Tween-80 (TW80)
(Fig. 1.1 reports their structural formula) mainly because they are widely use as
excipients in pharmaceuticals.
Fig. 1.1: Structural formula of Tween-20 (upper panel) and Tween-80 (lower pannel); for both
molecules w+x+y+z=20.
As models of truly lipophilic compounds I use β-carotene (BC) and clofazimine
(CFZ) (their structural formula are reported in Fig. 1.2): they absorb in the visible
range, thus their quantification down to nmol can be achieved by spectrophotometric
method.
BC is the major retinol precursor, providing a substantial proportion of the vitamin
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Fig. 1.2: Structural formula of CFZ (left panel) and BC (right panel).
A in the human diet [9] [10]; moreover, due to its well-established antioxidant
properties, it protects against some human cancers and cardiovascular diseases [11,
12], arteriosclerosis, macular degeneration and other age related diseases [13].
Having octanol/water partitioning coefficient (logP) equal to 17.5 [14], it is virtually
insoluble in water [15] and tend to form microaggregates in aqueous environment
which can no longer be enzymatically converted [16]. To increase its aqueous
solubility, BC has been successfully encapsulated in liposomes [17], niosomes [13]
and alginate-pectin hydrogels [18]; furthertmore it may be solubilized by microemul-
sions [19], nanoemulsions [20] nanodispersions [21] and by complexation with
cyclodextrins [22]. I exploit the facts that BC is insoluble in aqueous media and
that it is a delicate molecule (as it is rather sensitive to heat, light and oxygen [23])
to investigate if the carriers (both Psi and NC hydrogels) are inert vehicles and if
they can protect this drug from degradation.
CFZ is a highly lipophilic antibiotic (logP=7.13) [24] with very low water solubility
(0.225 µg/ml) [25], that is routinely used for leprosy treatment [26, 27]. Its efficacy
against inflammatory, Mycobacterium tuberculosis and Mycobacterium avium dis-
eases are demonstrated as well as its in-vitro activity against other members of the
mycobacteria and other Gram-positive bacteria [28]. The undesired effects due to
its low solubility (such as drug accumulation in tissues and crystal-like drug inclu-
sions formation in macrophages [29–31]) stimulate the development of different
strategies to increase its solubility: CFZ salts [32], encapsulation into liposomes
[33, 34], water-soluble polymer carriers [25, 35, 36], conjugation onto modified
cyclodextrin [37] and amorphous solid dispersions [38].
1.2 Drug delivery
DD refers to approaches and systems designed to deliver pharmaceutical compounds
to safely achieve the desired therapeutic effect. There are several administration
routes by which a drug can reach the site of action and they are generally classified
as enteral (if the drug is delivered through the gastrointestinal (GI) tract, e.g. oral,
rectal), parenteral (if the drug is delivered by routes other than the GI tract with a
system-wide effect, e.g intravenous) and topical/local (when both the application
location and the pharmacodynamic effect is local, e.g. transdermal, inhalation).
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For several diseases, the oral delivery remains the preferred route because it is non-
invasive, can be self-administered, improves patient compliance and is among the
less expensive method. Furthermore, it can provide a long-term, continuous release
of the drugs using lower (and thus safer) concentrations resulting in much better
efficacy and fewer side effects compared to the intermittent injection therapy [39].
However, many pharmaceutical compounds suffer from poor bioavailability, so that
they are unsuitable for conventional oral formulations. Their low bioavailability
can be related to the physiology of the GI tract, that is characterised by the following
formidable barriers [40–44]:
1. chemical barrier: the pH value changes from highly acidic (pH 1.2-3) in the
stomach, to neutral or slightly alkaline (pH 6.5-8) in the intestine. Several
active ingredients are susceptible to the pH change which may cause drug
degradation.
2. physical barriers: the first physical barrier is represented by the mucus. It is
a complex aqueous mixture of glycoprotein, lipid, salts and cellular debris
produced by epithelial cells, that on one hand affords protection for the
underlying tissues from various environmental attacks, enzymes and other
chemical agents, on the other it may adversely affect the drug absorption.
The second physical barrier is constituted by the epithelial cell layer that have
to be crossed by the drugs to finally achieve the systemic circulation (either
blood or limph). The pharmaceutical compounds can pass through this layer
by paracellular or transcellular transport, but also by lymphatic uptake:
• paracellular transport: if hydrophilic and charged particles are small
enough, they may cross the epithelial cell layer by passing between the
cells through the junctional complex. Enhancers have been shown to
improve paracellular transport either via interactions with the negatively
charged cell membrane or by complexing Ca2+ involved in the structure
of tight junctions [45].
• transcellular transport: particles are absorbed by intestinal enterocytes
at the apical membrane and are subsequently released into the basolat-
eral compartment; the phospholipid bilayers of the cell membrane only
support the passive diffusion of lipophilic small molecule drugs, whereas
most of the hydrophilic particles are translocated by active transcellular
transport (i.e. endocytosis followed by exocytosis).
• lymphatic uptake: the particles are internalized by highly specialised
epithelial cells, the so called M cells of the Peyers patches; these cells have
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a unique anatomy and physiology that allow both the rapid delivery of
vaccine antigen directly to immune system cells and the drugs absorption
via the intestinal lymphatic system, so that the pharmaceutical compounds
are protected from hepatic first-pass metabolism (see next item).
To increase the drug permeability across the GI wall, the active ingredients
are often administered together with permeation enhancers.
3. enzymatic barrier (called first-pass or pre-systemic metabolism): the orally
administered drugs face the proteolytic degradation by GI luminal enzymes
and by enzymes located inside the intestinal cells (if transcellular transport
is involved). Additionally, the majority of the compounds enters the systemic
circulation via the portal vein and the amount of available drug is further
decreased by the liver enzyme system. To decrease the extent of pre-systemic
metabolism, the drugs are often administered with enzyme inhibitors and
for highly lipophilic compounds it is possible to relay on intestinal lymphatic
transport avoiding the hepatic fist-pass metabolism.
Futhermore, the GI tract is an aqueous environment so that poorly water soluble
drugs results in low dissolution rate and elimination of a fraction of the compound
prior to absorption, decreasing even further their bioavailability. The facts that an
estimated 40% of approved drugs and nearly 90% of the developmental pipeline
drugs consist of poorly soluble molecules [46] make the low solubility one of
the major problem encountered in formulation development of new drugs. To
increase the molecule solubility either chemical or physical modification of the active
ingredients and the use of the DDSs have been introduced. These strategies are
listed in Fig. 1.3 and described here below.
1.2.1 Chemical modification
Prodrugs Prodrugs are biologically inactive molecules that, once introduced into
the body, undergo chemical transformations (usually by enzymes) which activate
them; thus they are precursors of the active ingredients [47].
Salt formation Salt formation is one of the most common and effective method
of increasing solubility and dissolution rates of highly acidic and basic drugs [48].
However, this strategy cannot be applied to neutral compounds. When dealing with
weakly acidic or basic drug the salt formation may often not be practical and, even
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Fig. 1.3: List of different strategies used to increase drug water solubility.
when salts can be prepared, a decreased dissolution rate in the GI tract may be
achieved due to the reconversion of salts into aggregates of their respective acid or
base forms [49].
1.2.2 Physical modification
Polymorphs and co-crystals The majority of the orally administered drug products
is in crystalline state [50] and several efforts have been made to create new solid
forms, with superior solubility while preserving the pharmacological properties of
the active ingredient. Drug molecules can crystallize as either single- or multi-
component. Single-component crystals provide limited opportunity to modulate
the physicochemical properties of a compound since they are limited to polymorphs
whose solubility difference is typically less than two-fold (see Fig. 1.4 A and B).
Multi-component crystals (also known as co-crystals) are systems constituted by
the active ingredient and the coformer bonded together in the crystal lattice with
non-covalent interactions. They can be stoichiometric (as in Fig. 1.4) or non-
stoichiometric; either molecular (if the active ingredient is neutral, as in Fig. 1.4 C)
or ionic (for charged drug, as in Fig. 1.4 D) [51].
Fig. 1.4: Schematics of polymorphs (A and B) and co-crystals (C and D); blue shapes represent the
drug molecules (either neutral or charged), red shapes are the coformers and the gray
ones the counterions (present in case of charged drugs) (adapted from [51]).
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Nanocrystals One of the oldest strategies for improving drug solubility is the
particle size reduction. It has been demonstrated that the reduction of size below
1 µm in diameter gives rise to an increase in solubility (as reported in Fig. 1.5)
due to an increase in the solvation pressure and the disruption of solvent-solute
interaction which eases the solubilization process [52]. For this reason nanoparticles
composed of 100% drug and sized in the range from few nanometers to 1 µm
(the so called nanocrystals) have been developed. They can be produced either by
reducing the size of a large drug crystal or by aggregating molecules. Most of the
oral nanocrystal formulations are solid dosage forms (e.g. tablets, capsules with
pellets), but also liquid dispersions exist [53].
Fig. 1.5: Trend of drug solubility as a function of particle dimension (adapted from [53]).
Amorphous solids Amorphous solids have also been selected for use in drug prod-
ucts, since the transformation of a drug from the crystalline state to an amorphous
form leads to an increase in solubility; however, the high-energy amorphous state
is not stable and needs to be stabilized, for example using the amorphous solid
dispersion [51].
Solid dispersions Solid products consisting of at least two different components,
matrix and drug, are defined as solid dispersions [54]. The drug can be dispersed
molecularly, in amorphous or in crystalline particles; moreover the matrix can be
either in crystalline or amorphous state [55].
1.2.3 Drug delivery systems
DDSs are vehicles designed to carry the drug to the desired place, while preserving
the cargo integrity. They are used in several administration routes to improve drug
bioavailability (in the particular case of oral DD they are exploited to improve drug
stability, solubility and permeability) [56–59].
When dealing with orally administered carriers two different strategies can be
adopted:
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• the vehicles either adhere to the mucus layer or to the epithelial tissue releasing
their content; then the active ingredients penetrate the GI walls to reach the
systemic circulation;
• after being in contact with the mucosal surface, the carriers themselves either
enter the GI barrier to deliver their content inside epithelial cells or cross the
GI barrier to deliver the drug to the systemic circulation or even to the target
organ. The possible mechanisms to pass through the GI barriers are the same
described above for the active ingredients [39, 44].
Here I give an overview about DDSs surface chemistry and size that are crucial
characteristics to develop any drug carrier; furthermore, the diverse organic and
inorganic DDSs are summarised.
External surface functionalization
The outer surface of the carriers is of paramount importance and has to be designed
considering how it will interact with the physiological environment. Carrier solu-
bility, stability against aggregation, interactions with biomolecules and crossing of
physiological barriers have to be considered to maximize the efficacy and minimise
toxicity of the treatment [60, 61].
Concerning oral DD, an important challenge is to maximize the retention time in
the intestine to increase the absorption probability. Bioadhesive materials (such as
polyvinyl alcohol (PVA) or polyethylene glycol (PEG)) are used to increase the transit
time of the DDSs in the GI tract, resulting in prolonged time window either for the
release of the payload or for their absorption into the intestinal cells. Moreover,
enhanced drug absorption could occur because of the increased effective surface
area in contact with the intestinal mucosa upon material swelling: swollen material
fills the crevices of the mucous membrane and yields to a high local concentration of
the drug [62–64].
The particle uptake and translocation dependence on hydrophilicity and surface
charge of the carriers is still a controversial issue [65–68]; probably the complexity
of the interactions, that strongly depend on the system under investigation, does not
allow to obtain general rules.
A strategy that has been investigated to improve the carrier absorption across the
intestinal epithelium is to couple the vehicles with targeting ligands that are specific
for receptors expressed at enterocyte or M cell surface [69, 70].
If the orally administer DDSs are designed to enter the blood circulation, they finally
come in contact with blood cells and plasma proteins, therefore their surface may
experience non-specific protein adsorption (opsonization), making them more visible
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to phagocytic cells [71]. To reduce protein adsorption, prevent agglomeration and
increase circulation time a PEG coating can be exploited [71, 72].
Particle size
The in vivo distribution, biological fate, toxicity and targeting ability of DDSs is
determined also by the vehicle size [73], as it plays a key role in the adhesion to and
interaction with the biological cells [39, 74]; moreover, it affects the movement of
the carriers in and out the vasculature [75]. The particle size should be optimized,
depending on the administration route and the targeted cells: for carriers injected
into tissue or inhaled they should be smaller than 200 µm and 100 µm [76]. The
vehicles released into circulation can have dimensions up to 10 µm, but usually
they are much smaller (the smallest capillaries in the body are 5-6 µm in diameter
and the particles should be small enough to avoid aggregation and embolism). Once
in the bloodstream, nanocarriers smaller than 10 nm are rapidly cleared by the
kidneys or through extravasation, while larger nanoparticles have higher tendency
to be cleared by cells of the mononuclear phagocyte system (MPS) [71]. Oral
DDSs can have dimensions ranging from few nanometers up to few millimeters;
generally, nanoparticles have relatively higher intracellular uptake compared to
microparticles and, due to their small size and relative mobility, they are available
to a wider range of biological targets [77]. For example, in Caco-2 cell line 100
nm size DDSs showed 2.5 fold greater uptake compared to 1 µm size carriers and
6 fold higher uptake compared to 10 µm microparticles. Using a rat in situ intestinal
loop model, it has been demonstrated that the uptake efficiency of 100 nm vehicles
is 15-250 fold greater than larger (1 and 10 µm) microparticles [78]. Furthermore,
nanoparticles penetrate throughout the submucosal layers, while microparticles
predominantly remain in the epithelial lining [79]. The importance of size for
the biological fate of particles, has been investigated also for DDSs internalised by
the Peyers patches: the larger ones (>5 µm) are typically retained in the Peyers
patches, while the smaller particles escape this site to disseminate via the lymphatics
to more distant sites [80].
The dimensions of the carrier influence its absorption and its stability, too; in
fact during storage smaller particles have greater tendency to aggregate. Particle
dimensions affect also the drug release profile: smaller particles have a larger
surface/volume ratio, so that most of the drug is at or near the carrier surface and
this is reflected in a faster drug release. On the other hand the larger DDSs allow
more drug to be encapsulated per particle and give slower release [58, 81].
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Organic DDSs
The most investigated materials use to fabricate organic DDSs are polymers and
lipids and carriers with diverse geometries can be obtained (their basic realizations
are reported in Fig. 1.6).
Fig. 1.6: Schematics of the most used organic DDSs: A) sphere, B) capsule, C) micelle, D) emulsion,
E) liposome, polimerosome, niosome, F) dendrimer and G) cyclodestrin.
Spheres They are classified in lipid spheres, polymeric spheres and polymeric
hydrogels.
The most common lipid-spheres are the solid-lipid nanoparticles (SLNs), that pos-
sess a solid lipid matrix core and the nanostructured lipid carriers (NLC), whose
matrix is composed of both solid and liquid lipids that improve drug loading and
increased stability on storage thereby reducing drug expulsion. Both these vehicles
are stabilized by surfactants or polymers to prevent particle agglomeration and
opsonization [82, 83].
Polymeric-spheres possess a core structure which can be varied by changing the
composition of the hydrophobic and the hydrophilic blocks on the polymer chains.
They are mainly produced by solvent evaporation, emulsion polymerization and
sedimentation polymerization [84, 85].
Polymeric hydrogels are obtained if the cross-linked networks of hydrophilic poly-
mers absorb large amount of water (up to 90% of their weight) while keeping the
3D structure of the polymer network (more details cane be found in Chap. 3.2).
Capsules Capsules are systems characterized by a core-shell structure. The core is
usually constituted by water or oil (these capsules are fabricated starting from w/o or
o/w emulsion), but also SLN and polymeric spheres are used. The shell is obtained
through interfacial polymerization, interfacial precipitation or LbL deposition. Even
if the majority of the capsules have a polymeric shell, also entirely lipidic capsules can
be prepared: they have an internal liquid or semi-liquid oil core and an external lipid
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layer that is solid at room temperature. These lipidic capsules should be stabilized
by surfactants or by polymers to prevent particle agglomeration and opsonization
[82, 84, 86–89].
Micelles Micelles are thermodynamically stable aggregates of amphiphilic molecules
in water, which under certain conditions self-aggregate to minimize their surface
energy, creating a hydrophobic core with a hydrophilic outer surface. Shape and
dimensions of these carriers depend on the type of molecules and the environment.
The majority of the micelles are made either of lipids (e.g. phosphatidylcholine and
bile salts) or of amphiphilic copolymers [90, 91].
Emulsions Emulsions can be obtained when a third component that is insoluble in
water (e.g. oil) is added to the water-amphiphile mixture. Under certain conditions
a stable, transparent and isotropic phase is obtained that contains large quantities
of both water and oil. Depending on whether the system is thermodynamically or
kinetically stable, one can distinguish between micro- and nano-emulsion. Recently
it has been developed the so called self-emulsifying DDSs (SEDDSs) that are used
for oral DD: drug, oil and large quantity of surfactants are inserted inside a gelatin
capsule; upon dilution with water these three ingredients form an emulsion [92].
Liposomes, polimerosomes and niosomes Liposomes, polimerosomes and nio-
somes are hollow shell carriers constituted by a double layer membrane enclosing
a hydrophilic environment, that enable the encapsulation of water-soluble molecules.
Hydrophobic drugs can be segregated in the vesicle membrane. Liposomes are
constituted by one or more bilayers consisting of amphiphilic lipid molecules concen-
trically oriented around an aqueous compartment [93]. Polymersomes differ from
liposomes by the fact that the membrane is made of amphiphilic block copolymers
[94], while that of niosomes results from the self-assembly of hydrated surfactant
monomers [13].
Dendrimers Dendrimers are nano-sized monodisperse polymeric molecules with
a typical branched structure that grows as a kind of "L-system" around an inner
core. They are made of several layered building blocks formed by repeated units and
multiple peripheral functional groups. The dendrimer interior is usually hydrophobic,
whereas the exterior surface is hydrophilic [95].
Cyclodextrins Cyclodextrins are cyclic oligosaccharides with a hydrophilic outer
surface and a hydrophobic central cavity. The fact that these molecules are relatively
large with a number of hydrogen donors and acceptors, prevent their permeation
through the lipophilic membranes. They are mainly used as complexing agents since
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they increase drug water solubility, enhancing their bioavailability and stability [96,
97].
Inorganic DDSs
Here I give a brief overview about metallic, carbon-based and ceramic nanocarriers;
details can be found in literature [58, 81, 98–100].
Metallic nanocarriers Metallic nanospheres (in the range 1-200 nm) and nanocap-
sules (hollow metal nanoshells) are often made of gold, silver, platinum, palladium
gadolinium and nickel. These carriers are characterized by large surface area that
enables the incorporation of high drug amount (a 2 nm Au nanoparticle could, in
principle, be conjugated with hundred drug molecules). The possibility to modify
their surface with various functional groups enable both drug loading and targeted
DD. Metallic carriers are not biodegradable and their toxicity is still of concern.
Carbon-based nanocarriers Carbon nanotubes and fullerenes are hollow, cage-like
architectures that have received much attention recently, even if some studies suggest
a possible toxicity of these materials.
Carbon nanotubes are obtained by self-assembling sheets of atoms rolled up in
tubular shape. It is possible to fabricate both single-wall and multi-wall carbon
nanotubes. The first are constituted by a single cylindrical graphite sheet (diameters
in the range 0.7-1.5 nm), while the multi-wall carbon nanotubes are characterized
by several (from 2 to 30) concentric tubes; the diameters for the inner tubular layer
is in the range 2-10 nm, yet the resulting external diameter range from several
nanometers to tens of nanometers (an extra thickness of about 0.7 nm is added for
each extra layer).
Fullerenes are carbon allotropes constituted by tens of atoms resulting in polygonal
structures with diameters in the order of 1 nm. Their geometry and size make
them appealing as DDSs, provided that they are subjected to a proper surface
functionalization to render them biocompatible.
Ceramic nanocarriers Ceramic nanocarriers are porous vehicles made of silica,
alumina and titania. They are characterized by a high drug loading capacity, due
to their very large surface area and pore volume. They are very stable against
chemical (pH), physical (heat) stress and in aqueous environment. The silica
nanoparticles are the most investigated: they are synthesized in basic or acidic
conditions through polymerization of silica species on surfactant template, which is
then removed by high temperature calcination or organic solvent extraction. The fact
that the mesoporous silica-based framework is produced by a sol-gel process, allow
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to control very precisely the particle size. The first mesoporous silica carriers used
in DD was MCM-41 (Mobil Composition of Matter-41) and later also SBA (Santa
Barbara Amorphous), HMS (hollow mesoporous sphere) and MSU (Michigan State
University) have been employed as DDSs.
1.3 Mathematical models of diffusion
Given the huge amount experimental trials needed to develop and optimize a
pharmaceutical product, the availability of mathematical models to describe the
release profile of the drug, would save large amount of time and help in reducing
costs. Drug diffusion models are classified in two main families: mechanistic
and empirical. Those based on physico-chemical phenomena, such as diffusion,
dissolution, swelling, erosion, precipitation and degradation of the DDS are defined
as mechanistic mathematical theories; depending on the complexity of the resulting
set of mathematical equations, either analytical or numerical solutions can be derived.
Generally, by increasing the model complexity, the accuracy of a mathematical theory
is increased, however too complex models might be cumbersome to use. In the
case of empirical models, the mathematical treatment is not based on real physical,
chemical or biological phenomena. Although, no or very limited insight into the
underlying drug release mechanisms can be gained, these theories are often used to
compare different types of drug release profiles, yet caution must be paid to draw
mechanistic conclusions or to make quantitative predictions.
Here I give an overview about the modelling of diffusion-controlled DDSs, neglecting
carrier erosion, swelling and degradation.
Diffusion is the spontaneous net movement of molecules along the concentration
gradient. Fick’s laws are used to quantify the diffusional mass transport: the first
law describes the steady-state diffusion, i.e. when the concentration within the
diffusion volume depends only on position and does not change with respect to time,
while Fick’s second law describes the non-steady state diffusion.
Fick’s first law relates the diffusion flux (J) (i.e. amount of drug particles that passes
through a unit area per unit time) to the position-dependent drug concentration
(c) under the assumption of steady-state:
J = −D · ∇c (1.1)
where D is the drug diffusion coefficient (also called diffusivity). The minus sign
shows that diffusion tends to nullify the concentration gradient.
The Fick’s first law is not sufficient to completely solve the problems of diffusion,
since the diffusional flux can modify the concentration gradient that, often, is
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time dependent. Starting form the first law and taking into account mass balance
considerations, the Fick’s second law can be derived:
∂c
∂t
= −∇ · J = ∇ · (D∇c) (1.2)
where all the parameters have the same meanings as in the first law, except that c
is the time- and position-dependent drug concentration and t is time.
Generally the mathematical treatment of the Fick’s second law is heavily simplified
if "perfect sink conditions" are assumed (i.e. very dilute and well stirred solutions
are used in such a way that the released drug is immediately carried away from the
device into the fluid) and if D is constant (matrix erosion, swelling and degradation
might give rise to a time, concentration and position dependent D), so that Eq. 1.2
can be rewritten as:
∂c
∂t
= D · ∇2c (1.3)
As for any differential equation, both initial and boundary conditions have to be
supplied, to solve it. The solution of the diffusion equation is the drug concentration
profiles during the release (i.e. c(t, x, y, z)); by integrating this solution it is possible
to obtain the amount of drug released at time t (Mt). Usually it is normalised with
respect to the amount released at infinite time (M∞), obtaining the fractional release
of the drug, MtM∞ .
When dealing with diffusion-controlled delivery systems, it is crucial to distinguish
between reservoir and monolithic systems. In the "reservoir system" or "core-shell
system" the drug is located at the center of the dosage form and is surrounded by
a membrane that constitute the release rate controlling barrier, so that the drug
depot and the membrane are physically separated. In the case of "monolithic system"
(also called "matrix system") the drug and the release rate controlling material are
homogeneously distributed throughout the device. Here only monolithic systems
are reviewed and details about reservoir dosage forms can be found in literature.
Another important information deals with the initial drug concentration inside the
device: if it is below the drug solubility the dosage form is referred as "solution",
while if it is above the device is called "dispersion". Moreover, the DDS geometry
significantly affects the resulting drug release kinetics; here slab (i.e. thin film with
negligible edge effects) and sphere are discussed, yet other geometries are reported
elsewhere [101–103].
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1.3.1 Mechanistic models
Monolithic solution
One of the most common case is the one of a drug homogeneously dispersed inside
a matrix, thus Fick’s second law is subjected to the following initial and boundary
conditions:
• the drug is initially uniformly distributed throughout the matrix;
• the initial drug concentration is below its solubility;
• the drug D is position and time independent;
• perfect sink conditions are maintained throughout the experiment.
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where Mt and M∞ represent the absolute cumulative amounts of drug released at
time t and at infinite time, respectively; L the slab thickness and R the radius of
the sphere.
Monolithic dispersion
Higuchi [105] considered the drug release from an ointment thin film into the skin,
with the following conditions:
• the initial drug concentration within the system is much higher than the drug
solubility within the matrix (i.e. pseudo-steady-state);
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• the geometry of the carrier is that of a thin film with negligible edge effects
(one-dimensional diffusion);
• the size of the suspended drug particles is much smaller than the film thickness;
• the carrier material does not swell or dissolve;
• the drug D is time and position independent;
• perfect sink conditions are maintained throughout the experiment.




(2c0 − cs)csDt (1.6)
where A the surface area of the film exposed to the release medium, c0 and cs
the initial drug concentration and the solubility of the drug in the carrier material,
respectively. The Higuchi equation was initially developed for a slab that releases
the drug through one of the two faces: a prefactor 2 should be added if the release
occurs through both sides of the thin film.
Baker and Lonsdale [106] presented an implicit mathematical equation to extend


























corresponds to the point when no more undissolved drug is present inside the device.
Afterwards, the release should be described using the infinite series expression (Eq.
1.4), yet this accounts to the very last part of the release process (especially when
c0  cs) [102].
A very similar approach has been proposed by Koizumi and Panomsuk [107] to
obtained an approximate equation that can be used when dealing with spherical
devices. Eq. 1.8 has the advantage to be an explicit form, thus, it is easier to solve:
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Mt = 4πd2
[√











where d is the beads diameter. Obviously, also this model is only valid as long as
the drug concentration in the matrix largely exceeds its solubility.
The square-root time dependence
The solution to Fick’s law obtained in the form of a trigonometric series in the case
of thin film (Eq. 1.4) can be rewritten in terms of an error function series, that is


















where ierfc(x) represents the integrated complementary error function of x.
For small times (i.e. Mt/M∞ < 0.60) the second term in the brackets vanishes, so








A proportionality between the cumulative amount of drug released and the square-
root of time is obtained both when drug delivery is approached by the Higuchi
equation (see Eq. 1.6) and by solving the Fick’s low for a slab monolithic solution (see
Eq. 1.10); this means that a square-root of time dependence of the drug transport
can be based on very different physical circumstances (dispersions versus solutions).
However, since the dominating release mechanism in both cases is diffusion, this
proportionality is commonly regarded as an indicator for diffusion-controlled drug
release. Yet, a square-root time kinetics does not necessarily mean that the underlying
drug release mechanism is diffusion-limited, in fact the superposition of other
physical-chemical phenomena (such as swelling, degradation, time- and position-
dependent changes in the diffusion coefficients) might result in an apparent square-
root of time kinetics [108, 109].
1.3.2 Empirical models
Despite mechanistic models make explicit connections between the drug release and
the physico-chemical parameters of the system, their use is limited to those DDSs
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that strictly fulfil the model requirements. For this reason empirical models are also
widely used.
0th-order model
When the drug diffused from the carrier at constant rate, its release is described by a
0th-order kinetic; assuming that there is no drug dissolved at time t=0, the equation
for 0th-order release is:
Mt = kt (1.11)
where k is a constant. In principle, this release profile leads to the best control
of drug concentration, improves patient compliance and reduces the frequency of
drug administration, so that 0th-order release is the ultimate goal of many controlled-
release drug delivery system.
1st-order model
This model has been introduced by Noyes and Whitney [110] when studying the
effect of concentration on the rate at which a solid substance dissolves in solution. In
accordance with the laws of diffusion, it is proportional to the difference between the




= k(cs − c) (1.12)
where k the is the first order proportionality constant.
After integration:
c(t) = A(1 − e−kt) (1.13)
where A is a constant.
Nowadays this model is generally used to describe the pharmaceutical dosage forms
which release the drug proportionally to the amount of drug remaining in its interior,
so that the amount of drug released by unit of time decreases with time. Since
it is difficult to conceptualize the underling mechanism on theoretical basis, it is
classified as an empirical model [111, 112].
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Power law model
To describe the first 60% of the fractional release from polymeric systems (with po-
sition and time independent D), Peppas and co-workers introduced a semi-empirical




where A is a constant incorporating geometrical and structural characteristics of
the system (drug and carrier) and n the release exponent, which might be indicative
of the transport mechanism, as reported in table 1.1.
Tab. 1.1: Exponent of the power law and drug release mechanism from polymeric DDSs
of different geometry.
Slab Cylinder Sphere Drug release mechanism
0.5 0.45 0.43 Fickian diffusion
0.5<n<1 0.45<n<0.89 0.43<n<0.85 Anomalous transport
1 0.89 0.85 Polymer swelling
There are two extreme for the exponent n, whose values depend on the system
geometry: if n = nmin the dominating mechanism is fickian diffusion, while n =
nmax indicates a swelling-controlled drug release. Values of n between nmin and
nmax can be regarded as an indicator for the superposition of both phenomena
(anomalous transport).
Weibull model




= 1 − e−atb (1.15)
where a and b are constants.
Although this model is used to fit and characterize diffusion-controlled experimental
data [114–117], it has two fundamental drawbacks. First of all, it does not capture
the correct limits imposed by the diffusion equation for short and long times;
secondly, although Papadopoulou et al. [118] developed a methodology to elucidate
the release mechanisms based on the value of b, the empirical Weibull function is still
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criticized because of the lack of a physical interpretation that could give a meaning
to its fitting parameters in the context of diffusion-controlled release [119].
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2Porous silicon
2.1 Introduction to porous silicon
Porous silicon (Psi) is a nano- to micro-structured material accidentally discovered
during electropolishing of c-Si by A. Uhlir in 1956 [120]. For decades it was
considered a non-stoichiometric oxide, a sacrificial material obtained in corrosion
processes. However, in 1990 the discovery of visible luminescence of Psi under
UV illumination by Canham [121] attracts a large research interest related to the
possibility to fabricate silicon-based active optoelectronic devices. Since then, Psi
properties have been largely investigated: its controllable pore size, its convenient
surface chemistry, the ability to modulate its refractive index as a function of porosity,
its large surface area and its efficient visible light emission make Psi a suitable
material for applications ranging from photonics and optoelectronic to biosensing
and biomedicine.
2.1.1 Psi fabrication and morphology
Psi is fabricated by electrochemical process that allows for the production of very
uniform porous layers with good reproducibility, without the need of complex set-up.
To perform electrochemical etching, c-Si is oxidized in HF solution (see Fig. 2.1).
Fig. 2.1: Schematic of the electrochemical etching set-up: c-Si is in contact with HF solution and
electrically contacted to an anode; a platinum cathode is immersed in the etching solution.
Generally the electrochemical reaction is controlled by imposing the current density.
Both p-type (p-Si) and n-type (n-Si) silicon can be exploited to fabricate porous
layers: the main difference relies on the fact that the semiconductor-electrolyte
junction is polarised in the opposite way when donor or acceptor doping are used.
Since the electrochemical etching is performed under anodic condition, p-Si is
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polarised in forward bias, while n-Si in reverse bias (see Fig. 2.2).
Fig. 2.2: The energetics of the semiconductor-electrolyte junction is determined by the relative
position of the energy levels: Fermi level (EF) for the semiconductor side and REDOX
potential (EREDOX) for the electrolyte side (VB and CB represent the semiconductor valence
and conduction bands). When semiconductor and electrolyte are brought into contact,
equilibrium is reached between the electrochemical potential of the two species. Since HF
solutions are used, the EF(Si) should be compared with the redox potential of F−, because
F− is the oxidant specie. In the case of n-Si (upper panel), since EF(n-Si)>EREDOX(F−), the
electrons flow from the semiconductor to the solution; this creates a positively charged
region ("space charge region" or "depletion layer", indicated as W ) in the solid material
near its surface. The resulting electric field is shown by the upward band-bending with
respect to the level in the bulk semiconductor. In the case of p-Si (bottom panel) EF(p-
Si)<EREDOX(F−), yet a similar discussion can be done, considering holes instead of electrons:
W is negatively charged and the bands are bent downward. In both cases, when equilibrium
is reached, an energy barrier for the majority carriers is established in the junction (SB),
that resembles the situation described in the Schottky-model for semiconductor-metal
junction. The electrochemical etching is performed under anodic condition, that means
reverse biasing for n-Si and forward biasing for p-Si.
Despite the exact chemistry that occurs at the silicon surface during the electrochemi-
cal etching is still pending, a schematic chemical dissolution reaction path has been
proposed by Lehmann [122] to qualitatively describe the formation of pores under
commonly used etching conditions (see Fig. 2.3).
The model assumes that, after native oxide dissolution, the semiconductor surface
is covered by Si-H. A hole reaching the surface (either by diffusion or by an applied
electric field) weakens the Si-H bond and eases the dissolution of superficial silicon
atoms (the exact chemistry of the reaction products is still debated). The hydro-
genated surface is attacked by the HF species, forming Si-F bonds and gaseous H2 is
generated. The ionic nature of the Si-F bond reduces the electron density of the Si-Si
backbone atoms; these are sufficiently polarized to be broken by HF. The released
22 Chapter 2 Porous silicon
Fig. 2.3: Reaction model of the silicon oxidation (adapted from [123]). This scheme can be
summarised by the following reactions: Si+2F−+2h+ →SiF2 and SiF2+4F−+2H+ →
SiF2−6 +H2, where H represents a hydrogen atom and h stands for "hole".
gaseous SiF4 reacts with HF to form SiF2−6 . At the end of an HF etching, the Psi
samples contain primarily Si-H, Si-H2, and Si-H3 surface groups and only traces of O
and F [124–127]. This seems puzzling, considering that Si-F is thermodynamically
the most stable bond of all silicon chemistry (the relative strength of bonds increases
in the order Si-H<Si-O<Si-F [123]). Actually the hydrogen atom is much less
electronegative than fluorine and a hydride-terminated surface is less susceptible
to nucleophilic attack.
According to this model, holes are required at the semiconductor-electrolyte interface
to weaken the superficial silicon atoms bonds, allowing the corrosion to occur. In
n-Si the majority carriers are electrons, so that the holes should be artificially created
in order to sustain the electrochemical etching (at least in lightly doped substrates,
with resistivity higher than 0.1 Ωcm). This can be done by back illuminating the
semiconductor and to force holes to drift towards the surface by applying an electric
filed.
Despite being known since decades, silicon electrochemistry is still an active field
of research. For example recently it has been demonstrated that the electrochemi-
cal corrosion occurs in highly doped n-Si also without illumination [128]. In this
case the minority carrier concentration is not enough to explain why the corrosion
reaction occurs and an alternative holes formation mechanism has been proposed
[129]: holes can be generated at the surface by the tunneling of the valence band
electron through the space charge layer into the conduction band; the fact that
electrochemical corrosion of n-Si without illumination occurs only for high dopant
concentrations is because this mechanism is possible only when the band bending
is sufficiently large to make tunneling possible.
The Lehmann model does not take into account that the etching solution can con-
tain nucleophilic species that can compete with fluorine ions; in this case not only
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electrochemical but also chemical etching occurs. The chemical etching proceeds
by the formation of an oxide that is dissolved either by HF or by hydrolysis [123].
However, the chemical etching can be neglected, unless significant quantities of
Si-O species are formed; this happens when oxidants are added to the HF solution
or when very high current density are used so that the HF diffusion to the silicon
surface can not keep up with the rate of delivery of valence band holes (the so called
"electropolishing").
The Psi formation region and the electropolishing regime can be clearly distinguished
looking at a typical iV curve, as that reported in Fig. 2.4. For current densities below
a certain threshold Psi is obtained. Above the so-called "electropolishing peak" the
current density is so high that the silicon interface exposed to the acid is homoge-
neously and completely removed. The electropolishing can be exploited to lift-off
the porous layer by applying a burst of current after its formation.
Fig. 2.4: Typical Psi iV curve: for current density below the electropolishing peak, the pores grow
in a stable manner.
It is generally accepted that the initiation centres for the formation of the pores are
the defects on silicon surface, where localized regions of large current density form.
[130]. The high density of nucleation sites is reflected to the fact that the first few
tens of nanometers of the superficial porous layer (called "transition layer") have a
pore distribution that differs from the one representing the steady growth condition
(see Fig. 2.5 taken from [131]). The superficial pores stop their growth because
the larger ones collect more carriers than the smaller, increasing their growth rate.
The depletion layer that forms around these larger pores collect all the carrier so
that the smaller have no more holes available.
Fig. 2.5: Schematic of transition layer and steady growth condition.
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The great control over porous structure enabled by electrochemical corrosion, makes
Psi very advantageous compared to other porous materials. Of particular importance
are the following parameters:
1. pores grow along selected crystalline directions;
2. the porosified layer is passivated against corrosion and an increase in etching
time is reflected in porous layer thickening;
3. c-Si doping level determines the order of magnitude of the pore size; a finer
control on pore dimensions can be achieved tuning the HF concentration and
the value of the current density.
Once a pore begins to grow, the small radius of curvature at its bottom generates a
region of enhanced electric field that attracts valence band holes: the dissolution
occurs faster at the pore tip, creating a tubular structure that propagates along the
high atomic density direction. Using (100) c-Si wafer orientation, the pores grow
perpendicular to the substrate surface and run parallel one to each other; the pore
branching is generally limited, unless high current densities are used (as discussed
later on). Instead, with (110) and (111) c-Si orientations, the pores form a complex
and three-dimensional network with quite well-organized pores, nevertheless their
structure is less homogeneous and they have found limited use so far [132].
A peculiar aspect of Psi formation is that the porosified layer is passivated against
further electrochemical etching: once formed, the pores do not redistribute or
collapse and the porosity remains approximately constant over the whole layer
[133]. In fact, when the depletion zones of two adjacent pores meet each other,
the current flow is pinched off (since holes cannot reach the silicon surface) and
further silicon dissolution is blocked. Thus the increase in etching time causes the
porous layer to thicken and porosity variation is obtained using a time-dependent
current profile (see Fig. 2.6).
Silicon doping level is used to select the average size of the pores: macropores
(with diameters in the range of µm) are formed using lightly doped c-Si (ρ ' 10
Ωcm), mesopores (100’s nm) with moderately doped substrates (ρ ' 10−2 Ωcm)
and nanopores in heavily doped c-Si (ρ ' 10−3 Ωcm). Once the c-Si resistivity has
been chosen, a finer control on the pore dimension can be achieved by tuning both
the HF concentration and current density. The evidence that the increase in HF
concentration causes the decrease in pore dimensions can be related to the fact
that pore nucleation is a thermally activated process (activation energy of about
0.35 eV [122]). Thus, increasing HF concentration, the probability to activate a
dissolution process on a certain point is increased too; as a consequence, more
pores start to grow, causing the decrease in their average diameter. Considering
the dependence of pore size on current density an opposite behaviour is observed.
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In fact, if the current density is increased, the holes are not consumed at the pore
tip and they can contribute to the pore enlargement; when the current assumes
very high values, pore branching occurs, since the holes that are not completely
consumed at the bottom of the pore diffuse towards the surface stimulating the
etching along defined crystalline directions. As highlighted previously, when the
current is further increased the holes density is so high that the silicon atoms are
removed isotropically (electropolishing).
Fig. 2.6: Cross section SEM image of Psi sample obtained with a time-dependent current profile:
high porosity regions are the darker layers, while the lighter bands correspond to low
porosity layers. Pores maintain the same dimensions irrespectively of their depth, thus
demonstrating the Psi passivation.
2.1.2 Estimation of Psi porosity











where f indicates the fraction of silicon in the porous layer, d and n are the layer
thickness and refractive index respectively. na and nb the air and silicon refractive
index (in the IR region na=1 and nb=3.4).
To obtain n one can exploit the fact that the porous layer can be seen as a dielectric
mirror that creates interference effects, as shown in Fig. 2.7. When a light wave
impinges on the Psi surface, the reflected spectrum is characterised by well known
fringes. The quality of the interference of porous layer depends on the thickness
of layers, their refractive index difference, the number of layers and smoothness of
their interface. For a single thin layer, the interference pattern directly depends on
n and d, so that if one of the two is known (for example d can be obtained from SEM
analysis), the other can be calculated with the following expression [136]:
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Fig. 2.7: Schematic of the light beam reflection when it hits a layer with thickness d and refractive
index n with an incident angle θ.
d = N




where θ the angle of incidence and N the number of periods observed within the
wave-number region considered (W ). When the incident angle θ is 0◦ (as in the case
of the used micro-FTIR), Eq. 2.2 can be simplified to
nd ' N2 · W (2.3)
Another strategy to estimate the porosity is the gravimetric measurement, yet this
method is less accurate than the optical one, especially in the case of small samples.
2.1.3 Psi surface chemistry
The as-etched Psi spontaneously undergoes chemical modifications, thus a crucial
step in the Psi fabrication is its surface stabilization. This is achieved by either
oxidation or functionalization, as described below.
As-etched Psi and its surface oxidation
The limited stability of hydride species (Si-Hx) produces an unstable Psi surface that
spontaneously oxidise. Samples stored in air are contaminated by chemical species
(mainly oxygen and carbon), thus "aged" Psi contains a native oxide of highly variable
composition, reflecting its storage conditions [137]. It has been demonstrated that
the oxide growth on HF-treated silicon in air shows a logarithmic dependence on
time with a rate of about 5 Ȧ/decade (albeit initially the oxide formation is hindered
and there is a largely varying lag-time that prevents a precise control over oxide
thickness) [124]. The slow Psi surface oxidation by "ageing" may be accelerated
by either thermal or wet oxidation (known also as chemical/liquid fase oxidation).
These methods generate oxides with diverse structures, that are reflected for example,
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in the oxide densities: 2.26-2.45 gr/cm3 in the case of thermal oxide and 1.5 gr/cm3
when it is formed in DI water (to be compared with 2.33 gr/cm3 for silicon and
2.65 gr/cm3 for bulk SiO2). Also the oxide thickness is different: usually no more
than few nm for native oxide and that formed in water, while thicker oxides can
be formed by thermal oxidation (100’s nm) [138]. Thermal and wet oxidation are
widespread methods to obtain a hydrophilic and stable surface, since Si-O bonds
strength is considerably greater than that of both Si-Si and Si-H bonds. However,
despite the oxide layer enhances the surface stability, the Si-O bonds are susceptible
to hydrolysis due to their high polarity.
Psi surface functionalization
Depending on the type of functionalization that has to be performed, both fresh
and oxidized layers can be used (see Fig. 2.8).
Fig. 2.8: Schematic of oxidation, silanization and silylation reactions: silanization requires oxidized
Psi surface, while hydrogen terminated surface is necessary for silylation.
Silanization is used to attach organic species onto the oxide layer: the hydroxy-
terminated surface undergoes a condensation reaction with alkoxy- or cloro-silanes
to produce new Si-O-Si linkage (as reported in Fig. 2.8). To favour the condensation,
the temperature can be increased (e.g. 60◦C is used in this thesis).
Silylation consists in the substitution of a hydrogen atom by a silyl group (R3Si)
forming a Si-C bond. Although the Si-C bond strength is lower than Si-O, the non-
polar nature of Si-C makes the carbonized surface even more stable. On the other
hand this method does not produce a complete and uniform coverage and this fact
can compromise the surface stability [139]. Photochemical and thermal promoted
silylation have been demonstrated, using both alkenes and alkynes [140–142].
Once the Psi surface has been functionalized, further reactions can be used to impart
specific interaction/recognition properties, by adding diverse and more specific
chemical groups.
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2.1.4 Psi photoluminescence
Photoluminescence (PL) in an indirect gap material such as silicon is a very ineffi-
cient mechanism; moreover, since silicon band gap energy is 1.12 eV, the emitted
photons will be in the IR region. In nanomaterials the electrons are not free to move
in the 3D space as when they are in bulk silicon and due to this spatial confinement,
the potential to which the particles (electrons and holes) are subjected can be approx-
imated by a quantum well. The energy of the band gap is inversely proportional to
the potential well width [121], so that Eg(c-Si) < Eg(Psi); furthermore the smaller
nanostructures are characterized by a larger band gap energy (see Fig. 2.9).
Fig. 2.9: Schematic showing how Psi nanostructures affects PL.
The introduction of non-radiative surface states (silicon dangling bonds) or radiative
recombination centres quench the PL; this happens for example when the nanostruc-
tures are capped by an oxide layer [137].
Due to its visible PL, Psi became an attractive material in the field of electronics
and optoelectronics [133], since an efficiency up to 5% can be reached under UV
illumination at room temperature [140]. Electrically excited visible PL has been
studied for decades, but no breakthrough has been demonstrated [143]. Actually Psi
nanostructures have been reported to be luminescent across the entire UV-VIS and
near-IR spectra, although in these cases the origin of these luminescence bands can
not be explain with the quantum confinement model. The UV band [144] and the
blue-green luminescent emission [145, 146] have been observed only in oxidized
silicon nanomaterials and probably arise from contaminated or defective silicon
oxide, while the origin of IR emission radiation can be related to dangling bonds,
although no direct correlation has yet been demonstrated [147].
The fact the Psi is a photoluminescent material makes it a suitable material for simul-
taneous imaging and drug delivery to the disease site. It has been demonstrated
that, upon proper functionalization, the intrinsic luminescence of Psi is preserved
inside the cells, allowing the microparticle tracking without using molecular tags
[148].
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2.1.5 Psi biocompatibility
When dealing with inorganic materials for biomedical applications, one of the main
concerns is related to their possible toxicity. Regarding this issue, Psi offers promising
features for biological compatibility, making this material an interesting candidate
for DD applications. In aqueous environment, silicon undergoes hydrolysis forming
Si(OH)4 (orthosilicic acid), that is the natural bioavailable form of silicon and can
be simply excreted via the kidneys [149]. Fresh Psi can produce reactive oxygen
species (ROS), which result harmful for healthy biological tissues. However, the
ROS generation is an effect related to Psi surface chemistry, therefore a proper sur-
face functionalization can prevent this issue [150]. Studies involving intravenous
injection in mice reported that Psi is rapidly removed from the circulatory system
[151]; another work demonstrates that Psi microparticles are internalized by human
dendritic cells, without showing any toxic effect even at a concentration of 1 mg/mL
[148]. Concerning Psi for oral DD applications, it has been demonstrated that Psi
particles are stable even in the low pH of the stomach and that do not show any
uptake within the intestinal cell layer [152, 153].
2.2 Results on BC release from Psi
2.2.1 Characterization of Psi samples
To study the BC release from Psi, I use two diverse Psi etching conditions, as reported
in Tab. 2.1.
Tab. 2.1: Etching conditions used for Psi-A and Psi-B fabrication.
Psi-A Psi-B
Si wafer (n-type) 0.02 Ωcm 0.01 Ωcm
etching solution
16% HF, 16% H2O 5.5% HF in DI H2O
in ETOH +1 mL Triton X-100
current density [mA/cm2] 82 53
The obtained Psi morphologies are shown in Fig. 2.10. In the first case the pores
are branched, while the second type of Psi show pores with smoother surfaces. In
both cases the pores are not interconnected and their size is much larger than the
BC dimensions. Knowing the etching time, from the SEM cross sectional images I
obtain the etching rate. In Fig. 2.11 the cross sections of Psi-A etched for 900 sec
and Psi-B etched for 350 sec are reported: etching rates are 0.052 and 0.022 µm/sec,
respectively. As reported in Sec. 2.1.2, once the Psi layer thickness is known, from
the FTIR measurements (see Fig. 2.12) it is possible to estimate the layer refractive
index, that is the parameter used in the Bruggeman formula (see Eq. 2.1) to estimate
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Fig. 2.10: Psi-A (left) and Psi-B (right) SEM cross sectional images that highlight the different pore
shapes.
Fig. 2.11: Psi-A (left) and Psi-B (right) SEM cross sectional images.
the porosity. According to Eq. 2.1 and Eq. 2.3, Psi-A has n=2.2 and a porosity of
about 45%; while in the case of Psi-B I obtain n=2, that correspond to a porosity
of of about 55%.
2.2.2 Psi loaded by immersion method
In some cases, DDSs require the addition of drug during their synthesis (incorpora-
tion method), but when dealing with Psi carriers the drug loading is performed after
the carrier fabrication (adsorption-absorption method). This process has several
advantages such as: the loading can be performed at room temperature, the com-
pounds to be loaded are not exposed to harsh chemical environment, the maximum
loading capacity is determined by the Psi carrier porosity and not by stoichiometry
or other parameters of the synthesis of the carriers.
Among the adsorption-absorption methods, one distinguishes between immersion
and impregnation (also referred as incipient-wetness method). With immersion a
known amount of the drug is dissolved in the desired solvent and the carriers are
immersed in this solution. After the equilibrium is reached, the loaded carriers are
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Fig. 2.12: FTIR reflectance spectra for Psi-A (left) etched for 900 sec, that correspond to a layer
thickness of 46.5 µm and Psi-B (right) etched for 1200 sec, that correspond to a layer
thickness of 26.5 µm; the typical fringes are clearly visible.
separated from the solution. In the impregnation procedure a controlled amount of
drug solution is added to the carriers and allowed to infuse through capillary forces
into the pores. Drugs are dried within the pores during solvent evaporation [72].
In this section I report the results obtained with the immersion method using Psi-B
samples. The empty volume in each Psi chip is about 25 µL, that has been estimated
knowing the etched area (A=0.28 cm2), the layer thickness (h'16 µm) and porosity
(P'55%). I used PSi samples both as-etched (Psias-etched) and oxidised (Psiox) to test
if a different surface chemistry (hydrophobic vs hydrophilic) affects the amount
of loaded drug. Samples have been thermally oxidised by placing Psias-etched on
hot plate at 200◦ for 4 h and then dipped in H2O2 (30% w/w in H2O) for 24 h.
The low temperature stabilization has been chosen to keep the oxidation process
compatible with highly porous nanostructures that tend to collapse into bulk silica
upon high temperature treatment. The samples are loaded by submerging them
in 1.5 mL of BC solutions in tetrahydrofuran (THF) at known concentrations for
24 h (0.32, 0.38, 0.77, 0.88, 1.60, 2.80 and 3.22 mg/mL for Psias-etched; 0.32, 0.38,
0.77, 0.88, 1.89, 2.80 and 3.76 mg/mL for Psiox). The non-porous surface of each
chip has been rinsed with THF from the loading solution before placing the sample
in 1 mL THF for the BC release. After 30 min, the released solutions have been
spectrophotometrically analysed to quantify the amount of BC loaded in each sample
(the BC absorption coefficient in THF is ε=144000 L·mol−1cm−1). Each experiment
have been performed in triplicate.
By knowing both the BC concentration in the loading solutions and the empty vol-
ume of the Psi samples, I calculate the amount of BC loaded (neglecting surface
adsorption). Fig. 2.13 reports the quantity of BC released as a function of the
estimated amount that should have been loaded inside the pore.
Neglecting surface adsorption, the data are expected to be on the bisector (orange
line in Fig. 2.13); instead the results show that the released BC is 5 to 20 times larger
than the theoretical concentration of BC within pores. The experiments performed on
both hydrophilic and hydrophobic surfaces show no macroscopic differences on the
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Fig. 2.13: Quantity of released BC vs the estimated BC amount inside the pores: the blue-squares
show the release from hydrophilic Psi, whereas the red-circles are the data of hydrophobic
PSi. Orange line is the bisector.
amount of BC trapped inside the pores. Furthermore, the standard deviations (SD)
of the amount of BC released are very large. The comparison of these results with
those reported in the next section (see Sec. 2.2.6 for details), suggests that the large
irreproducibility obtained using the immersion methods is due to heterogeneous
nucleation (see Appendix for the basic concepts about nucleation).
2.2.3 Psi loaded by impregnation method
The large irreproducibility of the immersion method prevents its use for precise
delivery of known amount of drugs, thus I investigate if the impregnation method
produces better results.
Unless otherwise specified, the following procedure has been used for all the experi-
ments: soon after the etching, the sample has been loaded with a known volume of
BC solution at known concentration in THF. At time t=0 min, the loaded samples
are immersed in a cuvette with 3 mL of ethanol (ETOH) with a magnetic stirrer
(to mix the solutions and keep the perfect sink conditions). At predetermined time
intervals, the entire release volume is spectrophotometrically analysed to quantify
the BC concentration (the BC ε in ETOH is equal to 144000 L·mol−1cm−1). I nor-
malize the release curves according to the absorbance value of a reference solution
obtained by diluting the same amount of the loading solution used to impregnate
the Psi samples in 3 mL of ETOH. All release studies are carried out in triplicate.
Release from Psi with different morphologies and thickness
Even if pore size (about 100 nm) is much larger than BC dimensions, rough and
smooth pore surfaces might influence the BC released kinetics. To investigate this
aspect I fabricate Psi-A and Psi-B with an estimated thickness of 23 µm and 26 µm,
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respectively and I load them with 13 µL of 0.3 mg/mL BC in THF.
According to the normalized data reported in Fig. 2.14 (left panel), the different
Psi morphologies do not influence the BC released kinetics.
When using Psi layer with pores size in the nanometer range, the loading is not
uniform and several BC aggregates form on its surface, as can be seen in Fig. 2.14
(right panel). When dealing with truly nanopores (i.e. <10 nm), extremely diluted
loading solutions should be used to minimize the surface crystallization of the drug,
yet a very low amount of drug can be loaded in this way.
Fig. 2.14: Left panel reports the normalised BC release profiles from Psi-A (red-squares) and Psi-B
(blue-triangles); lines are guides to the eyes. Right panel shows a picture of truly nano-Psi,
where the macroaggregates at the coffee-stain edge are clearly visible.
Given the similarity of the releases from the two type of Psi, I investigate the relation
between the Psi layer thickness and the release kinetics. I fabricate Psi-A with an
estimated layer thickness of 46 µm and 23 µm and the samples have been loaded
with 13 µL of 0.3 mg/mL BC in THF.
Comparing the released curve obtained (see Fig. 2.15), a significant variation in
the BC released rate is observed: by increasing the layer thickness, the saturation
is retarded (i.e. at about 50 min using the thinner Psi, at about 100 min with thicker
Psi). This fact was expected as the molecules need to diffuse for longer length on the
most thick sample, but it suggests that, using this loading condition, BC molecules
are adsorbed quite homogeneously along the whole Psi walls.
I fit the data (Psi-A 46 µm, Psi-A 23 µm and Psi-B 26 µm) with both the mechanistic
model for slab (see Eq. 1.4) and the empirical 1st-order model (see Eq. 1.13);
Fig. 2.16 show the fitted curves and Tab. 2.2 and Tab. 2.3 report the values of the
parameters.
I use 50 terms in the summation of the mechanistic model and I verify that the
fit accuracy is not limited by such approximation. All parameters (Minf , L, D and
k) in both the models are left free during the fitting. Looking at Fig. 2.16 there
is no significant difference between the two models. According to Tab. 2.2, L
values are very close to the thickness of the samples and the order of magnitude
of Ds is the same for liquid in liquid diffusion (10−5 cm2/s), while for high weight
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Fig. 2.15: Normalised BC release profiles from Psi-A with different thickness: 46 µm (black-circles)
and 23 µm (red-squares); lines are guides to the eyes.
Tab. 2.2: Values of fitting parameters and R2 obtained using the mechanistic model for slab.
Psi-A 46 µm Psi-A 23 µm Psi-B 26 µm
M∞ 9.6 8.7 8.9
L [µm] 48 23 24
D [cm2/s] 4 · 10−6 1 · 10−5 8 · 10−6
R2 0.984 0.992 0.990
Tab. 2.3: Values of fitting parameters and R2 obtained using the empirical 1st-order model.
Psi-A 46 µm Psi-A 23 µm Psi-B 26 µm
M∞ 9.6 8.7 8.9
k [min−1] 0.04 0.4 0.3
R2 0.999 0.991 0.986
molecules D can be 100 times slower [154]. Even if the fit converges always to
the same parameters values (irrespectively from the initial guesses supplied to the
algorithm), the prediction intervals obtained for D and L are huge (107). On the
other hand, the 1st-order model produces much narrower prediction intervals (of
few %).
2.2.4 Layer-by-Layer on Psi
The PSi used in this work is characterised by large pores, which allow to load high
amount of drug, but there is the need for a strategy to avoid the initial burst release
and slow down the release kinetics. For this reason, I try to fabricate a multilayer
coating on the porous surface using Layer-By-Layer (LBL) assembly. This method
allows to deposit films on the substrate surface through the alternating adsorption
of oppositely charged polyelectrolytes from aqueous solutions via electrostatic in-
teractions [155].
In this thesis Poly(diallyldimethylammonium chloride) (PDADMAC) and Poly(sodium
4-styrenesulfonate) (PSS) with average molecular weights of 450 and 1000 kDa
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Fig. 2.16: Mechanistic model for slab (red continuous line) and empirical 1st-order model (black-
dotted line) are used to fit the normalised BC release form Psi-A 46 µm (upper panel),
Psi-A 23 µm (bottom left panel) and Psi-B 26 µm (bottom right panel).
have been chosen as positively and negatively charged strong polyelectrolytes. As an
alternative, I use laponite (LAP), a crystalline layered silicate that, when dispersed
in water, forms a colloid constituted by nanosized disc-shaped lamellae of about 30
nm in diameter and 1 nm thick. The edge of these platelets is positively charged,
while the surfaces are negative [156, 157]. The polyelectrolytes softness opposed
to the stiffness of LAP could give rise to different efficiency in pore sealing, reflecting
in diverse release kinetics.
ζ-potential analysis on Psi microparticles
In this section I report the ζ-potential measurements performed on Psi microparticles
in collaboration with Prof. Alessandra M. Bossi of the Department of Biotechnology
of the University of Verona. The obtained ζ-potentials are approximately corrected
values, that allow a semi-quantitative comparison among the various samples. For
each type of sample, if not otherwise specified, the measurements are performed
in triplicate.
Psi microparticles are obtained by grinding the Psi-A chips, followed by ultrasound
sonication for few minutes in 1:1=H2O:ETOH. The particles are left in this solution
for some hours to start their oxidation and ease their dispersion in water (as ETOH
increase the particle wettability in aqueous solutions). Then they are centrifuged
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(about 5000 g for 5 min) and dispersed in 30% H2O2 for 24 h to complete the oxida-
tion process. Oxidised microparticles are centrifuged and dispersed in 3 different
buffer solutions to verify their charge and stability at different pH. As reported in
Tab. 2.4 oxidised particles are negatively charged and their ζ-potential modulus is
sufficiently large to consider them as stable suspensions and to allow the deposition
of the first polymeric layer.
Tab. 2.4: ζ-potential values for oxidised microparticles at different pH.
Buffer ζ-potential [mV]
buffer ph 4,7 (sodium acetate) -22±2
buffer ph 7,4 (TRIS-acetate) -27±2
buffer ph 9.8 (CAPSO ) -33±2
To create the first positive layer, the oxidised Psi particles are immersed in a PDAD-
MAC solution at pH=7 and placed for 30 min on a shaker. I prepared various
samples that differ for Psi and PDADMAC concentrations; moreover I deposit the
layers with and without NaCl (0.5 M), since it has been reported that the presence
of NaCl increases both film thickness and its surface roughness [158, 159]. Details
about sample preparation conditions are shown in Tab. 2.5.
Tab. 2.5: Sample preparation conditions used to deposit the PDADMAC layer on oxidised
microparticles and the corresponding average ζ-potential values and SD.
Psi 1.25 mg/mL Psi 0.16 mg/mL
PDADMAC (mg/mL) ζ-potential (mV) PDADMAC (mg/mL) ζ-potential (mV)
5 31±2 5 32±3
1 28±2 1 32±2
5 with NaCl 32±2 5 with NaCl 31±2
1 with NaCl 30±2 1 with NaCl 27±2
After 3 rinses, the microparticles are dispersed in water. I dilute the PSi 1.25 mg/mL
suspensions to reach about the same concentration of the more dilute one (Psi 0.16
mg/mL), to have similar scattering from all solutions. The rinsing efficiency is
confirmed by conductivity measurements (0.030 ± 0.003 mS/cm in oxidised Psi-A
and 0.027 ± 0.005 mS/cm in Psi-PDADMAC). According to the ζ-potential averages
reported in Tab. 2.5, it is evident that the first positive layer has been formed on Psi
microparticles, but no significant difference emerges when comparing the different
fabrication conditions. For further analysis I choose 0.16 mg/mL of Psi-A and 1
mg/mL of PDADMC.
Before depositing the second layer, I investigate the Psi-PDADMAC microparticles
stability in various buffers (see Tab. 2.6): the ζ-potentials remain positive at dif-
ferent pH and their moduli are slightly larger than those of naked oxidised powders.
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Tab. 2.6: ζ-potential values for PDADMAC-particles at different pH.
Buffer ζ-potential [mV]
buffer ph 4,7 (sodium acetate) 38±2
buffer ph 7,4 (TRIS-acetate) 32±2
buffer ph 9.8 (CAPSO ) 26±2
To deposit the second negative layer, the PDADMAC-particles are suspended in buffer
at pH=7 with either LAP or PSS and placed for 30 min on a shaker. The tested LAP
concentrations are 0.5, 1 and 5 mg/mL, while in case of PSS I use 1 and 5 mg/mL.
After 3 rinses, the microparticles are dispersed in water; the measured ζ-potentials
are reported in Tab. 2.7 and Tab. 2.8 together with the number of tested samples.
The fact that the ζ-potentials of microparticles dispersed in LAP suspensions are
positive, indicates that the second layer does not formed. Concerning the PSS layer,
negative ζ-potentials have been obtained only in 9 out of 15 samples. Given the
poor reproducibility of the PSS second layer (LBL formation occurs only in 60% of
the attempts), I do not proceed for subsequent layers.
Tab. 2.7: Sample preparation conditions used to deposit the LAP layer on PDADMAC-
particles, number of tested samples, corresponding average ζ-potential values
and SD.




Tab. 2.8: Sample preparation conditions used to deposit the PSS layer on PDADMAC-
particles with the ζ-potential values obtained for each sample.


















Release from Psi covered with LBL
To study the effectiveness of PDADMAC-PSS LBL in tuning drug release, I use
oxidised Psi-A samples 45 µm in thickness. Each Psiox has been loaded with 20 µL
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of 0.3 mg/mL BC in THF; the BC used for experiments reported in this section has
ε=100000 L·mol−1cm−1 (this reduced value is due to a partial degradation of the
BC: see Sec. 2.2.7 for a detailed discussion about how it affects the release from Psi).
After the loading the Psiox samples have been subjected to either of the following
procedures:
• they are immediately placed in ETOH to monitor the BC release;
• they are placed in a PDADMAC solution (5 mg/mL in buffer at pH=7) for 30
min and then (after the rinsing in DI H2O) in a PSS solution (5 mg/mL in
buffer at pH=7) for 30 min. Before monitoring the BC release, the samples
are rinsed in DI H2O (denoted as PSiLBL).
The normalized release curves are reported in Fig. 2.17.
Fig. 2.17: Normalised BC release profiles from PSiox (green-circles) and PSiLBL (black-squares);
lines are guides to the eyes.
The amount of BC molecules released from PSiox is 80% of the loaded BC, while that
released from PSiLBL is about 70%. The lower amount of BC spectrophotometrically
detected in the release media of PSiLBL, can be due to the fact that, once loaded,
these chips have been placed in H2O that can partially oxidised the BC in the pores,
thus reducing its absorbance (as reported in Appendix). To verify this hypothesis, I
immerse the loaded PSi samples in H2O for 1 h (denoted as PSiaq) before monitoring
the BC release. The data reported in Fig. 2.18 confirm the hypothesis, since the
amount of BC released is about 70%.
2.2.5 Formation of BC aggregates on Psi surface during the
release in ETOH
Although in the previous experiments Psi samples have been loaded with small
amount of BC (few nanomoles), Psi is well known for its high loading capacity.
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Fig. 2.18: Normalised BC release profiles from PSiLBL (black-squares) and PSiaq (red-triangles);
lines are guides to the eyes.
When I try to increase the quantity of molecules loaded, I observe that, during the
release, BC forms aggregates on Psi surface giving rise to unreproducible experiments.
For this reason I investigate how loading conditions, surface chemistry and BC extent
of degradation affect the BC heterogeneous nucleation (see Appendix for the basic
concepts about nucleation). The Psi samples used for the following experiments
are Psi-A, 45 µm thick.
Aggregates formation dependence on BC concentration in the
loading solution
To load the as-etched Psi samples I prepare THF solutions of BC at different con-
centrations: 1.5, 0.3 and 0.17 mg/mL. Psi samples are impregnated with diverse
volumes of these solutions, so that different amounts of BC are loaded, as reported
in Tab. 2.9.
Tab. 2.9: Amount of BC loaded in Psi samples using loading solutions with different BC
concentrations.
loading solution [mg/mL] loaded BC [µg]
1.5 3.8 7.5 10.5
0.3 3.8 7.5 10.5 12
0.17 6.8 10.2 13.6
The porous chips are immersed in ETOH to monitor the BC release and during the
first few minutes of the release (about 3-15 min) in some of the samples I observe
the formation of BC macroscopic aggregates on the Psi surface (an example is shown
in Fig. 2.19, where the arrows point to the BC aggregates).
To note that during the loading such aggregates are not visible; moreover, in all
the experiments the release media are well stirred and the BC final concentrations
are much lower than the BC solubility in ETOH (i.e. when loading 3.8 or 13.6 µg, the
BC final concentrations are about 23 and 6 times lower than BC solubility [160]).
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Fig. 2.19: During the first few minutes of the release in ETOH, BC aggregates are clearly visible on
the surface of some Psi samples.
In Tab. 2.9, the loading conditions at which the aggregates are clearly visible on
the Psi surface are highlighted: by decreasing the BC concentration of the loading
solutions, larger amount of drug can be loaded without aggregates formation during
the release. Kinetics of BC release are reported in Fig. 2.20 and looking at these
data, the following considerations can be done:
• when no macroaggregates are visible, about 90% of the loaded BC is released
and the SD among different release experiments are less than 10% ;
• if macroaggregates form, only 40 to 60% of the loaded BC is released and the
SD increase substantially, up to about 30%.
Fig. 2.20: Normalised BC release profiles from PSi loaded with different amount of BC using loading
solutions with BC concentrations of 1.5 mg/mL (upper left panel), 0.3 mg/mL (upper
right panel) and 0.17 mg/mL (bottom panel): (about 4 µg blue-crosses, 8 µg red-circles,
10 µg green-squares and 13 µg black-triangles); lines are guides to the eyes.
To note that the solubility of these macroaggregates is extremely slow and variable:
they need from 24 h up to 35 h to completely dissolve.
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The experimental outcomes can be interpreted by assuming the poor reproducibil-
ity to be due to heterogeneous nucleation, that produces a broad distribution of
aggregates reflected into broader release kinetics and increased SD.
To quantify this effect I define the figure-of-merit (FOM) as the ratio between the
normalised released BC and the SD: loading conditions for which the BC release
is nearly complete and reproducible give rise to high FOM. According to the data
reported in Fig. 2.21, it is evident that the aggregates formation does not depend
only on the amount of BC loaded, but also on the BC concentration of the loading
solution. In fact, aggregates are clearly visible when only 3.8 µg of BC are loaded
using 1.5 mg/mL, while if I use 0.3 mg/mL their formation is evident when I load
at least 12 µg of BC. The samples loaded with 10.5 µg of BC using the 0.3 mg/mL
solution have a FOM'8 and do not form macroaggregates, however they release
slightly less BC, compared to the samples loaded with smaller BC amount (about
80% vs 90%) and its SD is a bit larger. Qualitatively, 10.5 µg might be the limiting
amount of BC that can be loaded using a 0.3 mg/mL solution without macroaggre-
gates formation.
Fig. 2.21: F.O.M as a function of the amount of loaded BC. When using the 1.5 mg/mL loading
solution (green-crosses) the F.O.M assumes always low values, irrespectively on the
amount of BC loaded; on the other hand when the more diluted loading solutions are used
(red-squares and blue-triangles), F.O.M values are high for low amount of BC loaded and
decrease for greater BC quantities. Lines are guides to the eyes.
If the release is performed in a much better solvent, such as THF (using the same
loading conditions), aggregates do not form and all the Psi samples released about
90% of the loaded BC (but in this case BC release is too fast to be monitored).
The results of this section demonstrate that, although the BC final concentrations in
ETOH are below its solubility limit, some loading conditions favour the occurrence
of supersaturated BC regions (both inside the pores and at pore openings) in which
heterogeneous nucleation occurs.
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Aggregates formation dependence on PSi surface chemistry
To investigate if there is a relationship between the aggregates formation and the Psi
surface chemistry, I compare the results obtained loading Psias-etched and Psiox with
7.5 and 12 µg of BC using a loading solution of 0.3 mg/mL. Since Psias-etched has
hydrophobic surface, while that of Psiox is hydrophilic, different interactions between
the BC molecules and the Psi surface are expected. According to the data shown
in Fig. 2.22 there is no significant difference: when 7.5 µg of BC are loaded both
Psi samples release almost all the molecules, while by increasing the BC amount,
aggregates form.
Fig. 2.22: Normalised BC release profiles from PSi with either hydrophilic or hydrophobic surfaces
loaded with different amount of BC (7.5 and 12 µg) using 0.3 mg/mL loading solution;
lines are guides to the eyes.
These experiments suggest that the BC nucleation-aggregation phenomenon on Psi
is mainly ruled by the surface energy due to the surface nanostructuring while it is
weakly related to the substrate surface chemistry.
Aggregates formation at the coffee-stain edges on bulk-Si
As a reference I perform a similar experiment by dropping a BC solution on a bulk-Si
sample: the coffee-stain effect leads to BC macroaggregates formation at the drop
edge. Although these aggregates seem very similar to that formed on Psi surface
during the release, the dynamics of dissolution demonstrate that the two aggregation
processes are different.
I create coffee-stain induced BC macroaggregates by dropping 20 µL of 1.5 mg/mL
BC solution in THF (4 drops of 5 µL each one). After solvent evaporation, I monitor
the BC dissolution in ETOH and the normalized data are reported in Fig. 2.23.
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Fig. 2.23: Normalised BC dissolution profiles from bulk-Si; lines are guides to the eyes.
BC is quantitatively dissolved in ETOH in less than 100 min. At the beginning the SD
are high, since diverse BC depositions give rise to BC aggregates with various dimen-
sions, which dissolve with different kinetics; but, at the end of the dissolution, the
variations in the amount of BC dissolved are small. I try to investigate the different
structure of these two type of macroaggregates by x-ray diffraction, unfortunately
the sensitivity of the instruments are not enough to collect a detectable signal from
BC crystals/amorphous aggregates.
Aggregates formation dependence on BC degradation extent
The fact that the dissolution of aggregates formed either during the release from Psi
or by the coffee-stain phenomenon on bulk-Si is different suggests to investigate if
the state of BC oxidation might have a role in the formation of different polymorphs
that dissolve at different rates.
I used BC with ε=70000 L·mol−1cm−1 and I load as-etched Psi with 40 µg or 35
µg using either 2 mg/mL or 3.5 mg/mL BC solution. Both experiments have been
performed in 5 mL of ETOH, to be far from the limit of BC solubility in ETOH: once
all the molecules have been released, the BC concentration is about 4 times lower
than its solubility (0.03 mg/mL). The normalised release curves are reported in Fig.
2.24. When BC 3.5 mg/mL is used, I observe the aggregates formation on the porous
surface during the molecule release, the decrease in the released BC percentage
(about 35% of the loaded BC) and the increase in the SD. On the other hand, using
the 2 mg/mL solution, no aggregates form, the released BC is about 70% of the
loaded one and the SD are less than 10%. The small SD obtained, lead to exclude
that the lower release percentage is due to the aggregates formation. The reduced
BC released might be due to partial degradation of the drug as described in Sec.
2.2.7.
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Fig. 2.24: Normalised BC release profiles from Psi loaded with degraded BC using loading solutions
of 2 mg/mL (blue-squares) and 3.5 mg/mL (red-circles); lines are guides to the eyes.
According to these data, when using degraded BC, the formation of macroaggregates
requires larger BC concentration in the loading solution than when non-degraded
BC is used. This is probably related to the presence of oxidised functional groups
on a substantial fraction of BC, which hinder its crystallization on the Psi surface
(probably due to the fact that the oxidised BC molecules are more hydrophilic).
2.2.6 Comparison between immersion and impregnation
method
By comparing the results between immersion and impregnation method, I note a
fundamental difference: assuming that the Psi, loaded using the immersion method,
releases the BC quantitatively (as the release has been performed in THF), I compare
it with the impregnation experiment with similar amount of BC loaded.
In average the samples loaded with the immersion method release about 5 nmol of
BC and the SD average value is 30%. With the impregnation method, I can load more
than 5 nmol without forming aggregate and obtaining SD less than 10% (e.g. sample
loaded with 3.8 mg using 0.3 mg/mL). This comparison suggests that the high SDs
obtained in most of the immersion experiments are due to aggregates formed inside
the pores, even if BC is loaded at concentrations lower than its solubility in THF
(10 mg/mL). The long time given to BC to arrange under equilibrium condition can
account for the aggregates formation. Since large SD are present only in immersion
experiments, they cannot be ascribed to non-specific absorption, otherwise I should
see similar SDs from impregnation releases, too.
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2.2.7 Release from Psi with different surface chemistry
The extreme hydrophobicity of BC is of interest to understand how it interacts with
either hydrophilic and hydrophibic surfaces. Thus, I fabricate a set of Psi-A samples
(45 µm in thickness), some of them are used as-etched to test a hydrophobic surface,
while others are oxidized, using different receipts, to obtain hydrophilic surfaces:
1. PSith (thermal oxidation): the Psias-etched have been placed on hot plate at 200◦
for 4 h;
2. PSiAPTES (thermal oxidation + APTES functionalization): after the thermal
oxidation, the Psi have been immersed in (3-Aminopropyl)triethoxysilane
(APTES) solution (1:100=APTES:toluene) on hot plate at 60◦ for 15 min.
3. PSiH2O2 (thermal + wet oxidation): after the thermal oxidation, the Psi have
been placed in H2O2 (30% w/w in H2O) for 24 h;
I rinse the oxidised/functionalized PSi with ETOH, before loading them with 20 µL
of 0.3 mg/mL of BC solution in THF. The release kinetics have been monitored by
immersing the loaded samples in ETOH. Fig. 2.25A reports the normalized release
data, while Fig. 2.25B show typical BC absorption spectra, acquired at the end of
the release.
Fig. 2.25: A) Normalised BC release profiles from PSias-etched (green-circles), PSiAPTES (red-triangles),
PSiH2O2 (blue-squares) and PSith(black-crosses); lines are guides to the eyes. B) BC typical
absorption spectra, acquired at the end of the release from the different Psi samples
(continuous lines) and reference BC spectrum (black dotted line).
To note that:
• PSith is the sample that release the smaller amount of BC (less than 60% of the
loaded one), while all the other samples release nearly completely the loaded
molecules; the small SD (about 10%) allows to exclude that the observed
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decrease in the release for the PSith is due to aggregates formation on Psi
surface.
• the UV tails of the spectra do not increase on samples with smaller released
amount of BC (see Fig.2.25B), suggesting that the π-coniugated structure of a
single BC molecule is not broken locally (e.g. by insertion of a single functional
group), otherwise absorbance spectra would shift as predicted by the empirical
Fieser-Kuhn rules for conjugated polyenes [161].
I try to recover the BC retained within the pores by immersing the PSith (after the
release) in THF and by disintegrating the porous layer using an ultrasonic treatment;
Psi micropartcicles are removed from the surnatant through a centrifuging (about
7000 g for 5 min). In the absorption spectrum of the surnatant there is no signal in
the BC region. This fact suggests that the 40% of the loaded BC in PSith has been
somehow degraded.
To understand whether the degraded BC molecules remain inside the porous layer
(adsorbed or chemically bound) or are released in the solvent, I can not relay on
spectrophotometic measurements, because the degraded BC molecules do not absorb
visible light. For this reason I perform NMR analyses, using stabilized CDCl3 as
solvent for both loading solution and release media. I load 6 Psias-etched and 6 Psith
with 10 µL of BC (1.5 mg/mL) in CDCl3, the release media obtained from these
two sets of samples have been concentrated to a final volume of 630 µL to increase
the molecules concentration to obtain a good S/N ratio in the NMR measurements.
The acquired data are reported in Fig. 2.26.
Fig. 2.26: NMR spectra of BC released from Psias-etched (blue line) and Psith (red line), normalized
to the CHCl3 peak. The inset shows a zoom of the peaks at 6.33 and 6.37 ppm, used to
quantify BC.
Both spectra show the typical, sharp peaks of molecular BC and there is no evidence
of BC degradation (e.g peak broadening or peaks related to oxidised species),
suggesting that no BC-polymer is present in the release media. However, the NMR
signals of BC released from Psith have a significantly reduced intensity with respect
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to those of BC released from Psias-etched. The two peaks at 6.33 and 6.37 ppm (due
to protons bound to C12) can be used to estimate the difference in the amount of
BC present in the two media by calculating their integral ratio: setting the value
of the integral for the BC released from Psias-etched to 100%, the integral of the BC
released from Psith is 63%. This value is very similar with the one obtained from
spectroscopic measurements (as shown in Fig. 2.25). Thus I conclude that Psith
heavily degrades the BC and it keeps the oxidized molecules inside the porous layer
(either adsorbed or chemically bound).
I try to get clues from the defects sensitivity to light by comparing samples which
are kept in the dark, under ambient light and more energetic radiation (UV light).
I load Psith with 20 µL of 0.3 mg/mL of BC solution in THF and I store the samples
for 2 h either in the dark or under ambient light: the samples release 40%±6%
and 43%±7% of the loaded BC, respectively. These values are lower than those
obtained when the release is performed immediately after the loading, suggesting
that even 2 h of storage in Psith substantially degrades BC and that visible light
does not influence the result. I do not perform the same experiments under UV
light, since I observe a very fast degradation of BC powder under this radiation
(by illuminating the BC powder for 1.5 h with a UV-LED light at 160 mW/cm2 I
obtain ε=135000 L·mol−1cm−1, while after 2 h in ambient light ε is still equal to
144000 L·mol−1cm−1). To test if UV light induces defects able to interact with BC,
I illuminate Psith with UV light for 2 h, then I load the sample with 20 µL of 0.3
mg/mL of BC solution in THF and I perform the release in THF. The released BC
is 55%±7% of the loaded one, so that the UV light irradiation does not have any
significant effect on BC degradation.
In the following experiments I compare the results obtained loading both Psias-etched
and Psith with BC characterised by different degradation extent (ε=140000, 100000
and 70000 L·mol−1cm−1). I load the porous layers with 20 µL of 0.3 mg/mL BC
in THF and I acquire the spectra at the end of the release. The data reported in
Fig. 2.27 show that when the Psi samples are loaded with degraded BC, the release
percentage is smaller than that obtained for non-degraded BC: the lower is the BC
ε, the more Psi degrades the BC molecules (both Psias-etched and Psith). This fact,
despite it is not a proof, suggests that BC degradation that occurs inside Psi might be
due to radical reactions.
2.2.8 Storage of BC in Psi
Although Psith fastens the degradation of partially oxidized BC (as it decreases the
ε of degraded BC in less than 2 h, the duration of a release experiment), when
stabilised Psi is loaded with non-degraded BC, its release is almost quantitative.
Considering the fact that Psi is opaque I think it might work as a protective carrier
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Fig. 2.27: Amount of BC released (normalized to the reference solution) from Psias-etched (blue-circles)
and Psith (red-squares) as a function of the loaded BC ε; lines are guides to the eyes.
for drug molecules. Furthermore, when Psi surface is covered by hydrogen it is
easily oxidized, thus (despite it is not suitable to protect drugs that can be reduced,
as reported in [162]) Psias-etched might be used as a sacrificial material to prevent
molecule oxidation.
To test these hypotheses I compared BC degradation of BC powder left in air, in THF
and loaded within Psi samples. A 0.3 mg/mL BC solution in THF has been prepared
to impregnate both Psias-etched and PsiAPTES with 10 µL. I keep the BC powder, the
loading solution and the loaded samples in the dark at room temperature for 2
weeks. After 15 days, I prepare a 0.3 mg/mL BC solution in THF using BC stored in
air and I estimate an ε of about 117000 L·mol−1cm−1. BC degradation is even more
consistent for BC stored in THF that has ε=77000 L·mol−1cm−1. Finally I perform
the BC release from the loaded Psi chips in THF: the amount of BC released from
Psias-etched and PsiAPTES is 15%±4% and 40%±7% of the loaded one, respectively.
The absorbance SDs are small, suggesting that no aggregates are formed, thus the
decrease in absorbance is due to BC degradation.
These experiments highlight that Psi, even if its surface has been properly stabilized,
degrades delicate molecules. In particular the stability of the drugs has to be
evaluated on a reasonably long time scale, as the degradation reactions can be rather
slow.
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3Nanocellulose
3.1 Introduction to nanocellulose
In recent years, the demand for products made from renewable and sustainable
resources increases the interest for cellulose-based materials. Cellulose is the most
abundant organic polymer on Earth; it is mainly present inside the plant cell walls,
but it is also secreted by tunicates (sea animals) and it can be found in some
algae and bacteria. This material is renewable, biodegradable as well as non-toxic;
furthermore it is highly sustainable since the traditional cellulose industry produces a
large quantity of cellulose wastes. Cellulose has been used for millennia in the form
of wood and plant fibres for building materials and for clothing. Recently, a deeper
knowledge of its properties and the ability to modify some of its characteristics (e.g.
functionalizing it to obtain high added value derivatives) enable to create cellulose-
based materials for coatings, membranes, pharmaceuticals and foodstuff. Moreover,
there is an explosive interest in isolating cellulosic materials with one dimension
in the nanometer range, since they combine important cellulose features with
the specific characteristics of nanoscale materials, such as: impressive mechanical
properties, tunable wettability, broad chemical modification capacity and reinforcing
capability.
3.1.1 Cellulose structure
Structurally, cellulose is a high molecular weight polysaccharide, constituted by
the linear repetition of anhydroglucose rings covalently linked together between
the oxygen bonded to C1 of one glucose and C4 of the adjoint ring (the so called
glycosidic bond), as shown in Fig. 3.1. Two anhydroglucose rings linked together
by glycosidic bond are called cellobiose and it is considered the unit of the cellulose
chain. Its chemical formula is (C6H10O5)n, where the number of repeated units
(n) is in the range 10000-15000 [163], depending on the cellulose source material.
The two rings forming the cellobiose do not lie exactly in the plane of the structure:
they have a chair conformation with adjoining glucose molecules rotated through an
angle of 180◦ about the molecular axis and hydroxyl groups are in an equatorial
position. In nature, cellulose is a material with a hierarchical structure: it is found
as assemblies of single cellulose chain, forming fibres, that are brought together
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through intra- and inter- molecular hydrogen bonds among the hydroxyl groups and
Van der Waals forces (see Fig. 3.2).
Fig. 3.1: Schematic of a single cellulose chain, showing the fundamental unit.
Fig. 3.2: Left panel shows the intra- (green lines) and inter- (red lines) chains hydrogen bonding
pattern in cellulose; right panel reports the schematic of the cellulose structure, from leaves
to molecules.
3.1.2 Cellulose biosynthesis
The multi-step process to synthesise cellulose is highly dependent on the source
considered; generally, inside the vegetable cell walls there are the so called terminal
enzyme complexes (TECs), from which cellulose is extruded. Each TEC is composed
of identical subunits and every subunit contains multiple catalytic sites. The resulting
cellulose fibril structure is strongly dependent on the catalytic sites, subunits and
TECs configurations. For cellulose produced by trees, each TEC is constituted by 6
subunits organized into six-membered rosettes and each subunit contains 6 catalytic
sites. Each catalytic site polymerizes a single chain of cellulose and the first step of
cellulose crystallization is the formation of a "mini-sheet" by self-assembling the 6
cellulose chains; then the 6 "mini-sheets" extruded by the subunits are self-assembled
in the so called "elementary fibril". The elementary fibril produced by each TEC is
constituted by 36 cellulose chains and it has a square cross section 3-5 nm in size.
Along a fibril there highly crystalline regions and amorphous domains with strikingly
different properties (see Fig.3.3, left panel). The elementary fibrils produced by 6
TECs are further assembled into the so called microfibril and a bundle of microfibrils
constitute the cellulose fibre (see Fig.3.3, right panel) [164–166].
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Fig. 3.3: Left panel reports the schematic of the steps that lead to wood elementary fibril synthesis;
right panel shows the schematic of the cellulose fibre hierarchical structure.
3.1.3 Crystalline cellulose
Crystalline cellulose produced in nature is called Cellulose I or "natural cellulose".
It can be found in two polymorphs: a triclinic (Ia) and a monoclinic structure (Ib),
that coexist in diverse proportions depending on the cellulose source [163, 167,
168]. Since Cellulose I has a structure that is thermodynamically metastable, it can
be converted in other polymorphs of technical relevance [167].
To date, the most accurate Ia and Ib lattice structures characterization has been
provided by Nishiyama and co-workers [169, 170]. The crystal structures of Ia
and Ib are reported in Fig. 3.4. When viewed along the cellulose chain axis, the
Ia and Ib show a nearly identical molecular arrangement and their unit cells have
a parallelogram shape (Fig. 3.4 A and B). The main difference between the two
polymorphs can be seen by looking along the direction indicated by the orange arrow
in Fig. 3.4 A and B. Ia and Ib show a different relative displacement of cellulose
sheets: for Ia there is a relative displacement of c/4 between each subsequent sheet
(Fig. C), while for Ib the displacement alternates between c/4 and -c/4 (Fig. D)[170,
171]. Ia and Ib share the so called "parallel up" configuration, meaning that all
cellulose chains are arranged in the positive c-axis direction of the unit cell, in such
a way that the C1→C4 link points in that direction [164].
3.1.4 Cellulose particle extraction
The isolation of cellulose micro and nanocomponents from the various cellulose
source materials is a two steps process. First of all the source material should be pu-
rified and homogenized; depending on the cellulose origin different pretreatment
methods are adopted. As an example, when dealing with wood and plant cellulose,
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Fig. 3.4: A) Cellulose I crystal and its cross sectional view; superimposed on the Cellulose I lattice
there are Ia and Ib unit cells, both with a parallelogram shape when looking down along
the chain direction (adapted from [172]). B) relative configuration of Ia with respect to Ib
unit cell, when viewed along the direction indicated by the orange arrow in Fig. A (adapted
from [171]). C and D) the displacement of the sheets for Ia of +c/4 (C) and Ib alternating
+c/4 and −c/4(D) (adapted from [172]).
the pretreatment involves the removal of matrix materials (e.g hemicellulose and
lignin), producing bleached Kraft pulps (that is the starting cellulose material used
in this thesis). In the second stage the "purified" cellulose is separated into micro-
and nanoparticles. There are three approaches usually exploited to isolate cellulose
particles: mechanical treatment, acid hydrolysis and enzymatic hydrolysis [164].
To mechanically extract cellulose fibrils high-pressure homogenizers, grinders and
ultrasonic treatments have been used. The high shear produced in these treatments
causes the cleavage of the cellulose structure, resulting in the extraction of long
cellulose fibrils, the so called microfibrillated cellulose (MFC). These are reminis-
cences of microfibrils. A filtration step is used to remove the larger unfibrillated
and partially fibrillated fractions.
The numerous hydrogen bonds are the main obstacle to separate cellulose microfib-
rils into thinner/shorter particles. To obtain smaller cellulose components the use
of never dried source materials [173] and chemical treatments [174–176] are used.
The never dried material is required as, upon drying, the spaces among microfibrils
is reduced and numerous hydrogen bonds are formed making the separation of these
aggregates even harder ("hornification"). After rehydration, most of these hydrogen
bonds remain, so that the reswelling does not produce the same "weakening" effect
obtained when using never dried cellulose. Moreover, to increase the interfibrillar
repulsive forces, it is possible to impart a charge to the surface of the never dried
cellulose. This can be done either through oxidation [174] or by functionaliza-
tion (e.g. carboxymethyl cellulose treatment [176]). Recently a pretreatment that
has received much attention is the so called 2,2,6,6-tetramethyl-piperidinyl-1-oxyl
radical region selective oxidation (in short TEMPO-oxidation). It is cost-effective,
"green" and simple to implement, as so it is the pretreatment of choice for this work.
Oxidized NC is easily disrupted and transformed into its nanoscale building blocks
via mechanical treatment, as sketched in Fig. 3.5 (left panel).
Several cellulose micro and nano-derivatives are obtained depending on: cellulose
source (biosynthesis), type and severity of the processes used for the extraction.
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Given such large flexibility, literature data are scattered (broad distributions of
lengths, widths and crystallinity) and even the nomenclature of these nanocompo-
nents has not been standardized yet [164]. Generally, the microfibrillated cellulose
correspond to the microfibrills, the nanofibrillated particles to the elementary fibrils
and the cellulose nanocrystals (CNC) to the crystalline regions (see Fig. 3.5, right
panel).
Fig. 3.5: Left panel show a schematic of CNC extraction through TEMPO-oxidation follow by me-
chanical treatment; right panel reports an AFM images of CNC.
3.1.5 TEMPO-oxidation
Despite the oxidation of alcohols by TEMPO has been known since the eighties
[177], only recently this approach has been exploited prior to the mechanical process
to facilitate the nanocellulose extraction [178]. TEMPO-oxidation is a method to
selectively convert the C6 hydroxyl groups of cellulose to aldehydes and subsequently
to carboxyl groups. Crystalline regions are not affected by this reaction because
their high packing density render them impermeable. The actual oxidant is the
nitrosonium ion (TEMPO+), which is reduced to hydroxyamine (TEMPO-OH) during
NC oxidation (see Fig. 3.6).
Fig. 3.6: TEMPO oxidation-reduction mechanism.
The four methyl groups in TEMPO sterically blocks its access to the secondary
alcohols, so that only primary alcohols are efficienty converted to carboxyl gropus
[179]. The oxidation of secondary alcohols by hypobromite is relatively low, so that
this competiting reaction can be neglected [180]. TEMPO penetrate the amorphous
regions to oxidised the cellulose chains, but it is unable to enter the crystalline
regions of cellulose, so that this oxidation method does not cause any changes in
the crystalline structure of the cellulose polymorphs Ia and Ib [181] and only the
primary alcohols on the surface of the crystallites are available for oxidation [182].
The catalist TEMPO and the cocatalist NaBr are dissolved with cellulose pulp at
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pH=10 and the oxidation starts by the addition of the primary oxidant, NaClO; the
reaction scheme of the alkaline TEMPO/NaClO/NaBr system is reported in Fig. 3.7.
Adding NaClO, TEMPO is oxidized to TEMPO+ by NaBrO (red and blue arrows).
Fig. 3.7: Reaction scheme of TEMPO-oxidation of primary hydroxyls to carboxyl groups via aldehides
(adapted from [183]).
TEMPO+ turns to TEMPO-OH by oxidising the alcohol group to aldehyde (magenta
arrows). Another TEMPO+ is consumed to convert the aldehide group to the
carboxylic group (black arrows). The two TEMPO+ are regenerated from the
hydroxylamine through the reduction of NaBrO to NaBr, then OBr− is reformed
thanks to hypochlorite ClO− (green and orange arrows). Since the pH is around
10, there is an exchange between H+ and Na+, turning COOH into COONa (purple
arrow). As the reaction proceed, the pH of the suspension decreses, so that NaOH
is continuosly added to mantain the pH at a constant value. When either all the
primary oxidant has been consumed (various oxidation degrees can be obtained
using different amount of NaClO [184]) or all the accessible primary alcohols have
been oxidised, the pH becomes stable. The pH is kept around 10 since reaction rate
reach its maximum at this pH value and it readily decelerates as the pH decreases.
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Higher pH are not used since the oxidised cellulose is prone to degradation (in
alkaline conditions the aldehyde groups are prone to β-elimination [185]). The
rate constant for hydroxyl oxidation to aldehyde is smaller than the rate constant for
the oxidation of aldehide to carboxy group, which leads to the conclusion that in
almost all cases the oxidised samples contain more carboxy groups than aldehides
[179].
The TEMPO-mediated oxidised pulp maintains an entangled fibrous form, so that
it is easy to wash the material removing the excess of chemicals [186].
3.2 Introduction to hydrogels
Hydrogels are solid-liquid systems in which a matrix (usually, but not necessary,
polymeric) is loosely cross-linked to form a three-dimensional network, which swells
when immersed in water but does not dissolved in it. The ability of hydrogels to ab-
sorb water is attributed to the presence of hydrophilic groups (-OH,-SO3H, -CONH-,
-CONH2-, -COOH) in the matrix structure, while their resistance to dissolution arises
from cross-links between network chains.
Hydrogels are receiving a great attention in several fields, such as water purification,
wound dressing, food additives and pharmaceuticals, drug delivery systems and
regenerative medicines, sealing and barrier materials (a complete review is [187]).
The hydrogel matrix is constituted by either natural or synthetic polymers. Syn-
thetic polymers (such as poly(ethylene glycol), poly(vinyl alcohol), poly(amido-
amine), poly(N-isopropylacrylamide), polyacrylamide and poly(acrylic acid) and
their copolymers) give hydrogels interesting properties, yet there is a strong effort to
replace them with natural alternatives to increase degradability and biocompatibility
[188]. Natural polymers used to fabricate hydrogels are hyaluronate, alginate, starch,
gelatin, gellan gum, chitosan, pectin, dextran and cellulose and their derivatives.
The hydrogels can be classified on the basis of the cross-linking method into chemi-
cal gels and physical gels: in the former case, the internal network is stabilized by
convalent bonds, while in the latter weak intermolecular forces (hydrogen bonds,
dipole-dipole, van der Waals forces) strengthen the network. Chemical gels are
usually prepared either using cross-linking reagents or by radical cross-linking. Be-
cause of the toxicity of many cross-linkers, radical procedure permits the synthesis
of safer hydrogels. Radicals are often created at will during the synthesis by UV
light [189], ultrasound treatment [190] and ionizing radiation (electron beam or
gamma rays) [191, 192]. Physically cross-linked hydrogels are formed spontaneously
under appropriate conditions that can be achieved changing parameters such as
temperature, pH and salt concentration.
Both cellulose and its derivatives are used to form either chemical and physical
hydrogels. Concerning those fabricated with native cellulose, the main difficulty is
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its low solubility, due to the strong hydrogen bonds network and the highly knot-
ted fibres. Some particular solvents help to reduce this limit [193], but the most
investigated strategy is to substitute the native cellulose hydroxyl groups by methyl
groups or hydroxylpropyl groups, so that some hydrogen bonds are prevented and
the resultant derivatives (e.g. methyl cellulose (MC), hydroxypropyl cellulose (HPC),
hydroxypropylmethyl cellulose (HPMC), and carboxymethyl cellulose (CMC)) be-
come water soluble. Although chemical gels can be fabricated [194], several efforts
have been made to produce physical gels, which require easier preparations and are
often safer. Relaying on temperature variations, it has been demonstrated that physi-
cal gels can be obtained from either native cellulose or its derivatives [195, 196],
yet cellulose-derived nanostrucutres are currently investigated for their possibility to
form physical gels through ionotropic gelation mechanism. The term ionotropy (ions
= ion, trepein = turn) has been introduced as a special case of gelation to describe
an unexpected behaviour of alginate that, in contact with a Cu2+ solution, formed
a hydrogel with parallel aligned, channel-like pores [197]. This process exploits
the ability of the carboxyl groups of alginate to chelate divalent ions, leading to the
formation of rigid three-dimensional lattices [198], as shown in Fig. 3.8.
Fig. 3.8: Schematic of the "egg-box" model for alginate gel formation: black lines represent the
alginate chains that are coordinated by the ions, depicted as orange circles (adapted from
[198]).
Since this first demonstration, ionotropic gelation has been exploited to fabricate
hydrogels using polymers other than alginate and also CNC. In particular, the TEMPO-
oxidized cellulose nanocrystals, contain both carboxyl and hydroxyl groups that
can be cross-linked by cations. The hydrogels characteristics can be tuned using
mono- di- or trivalent cations (e.g. Na+, Ca2+, Al3+), as the resulting gel stiffness is
proportional to the ratio between the valence and the radius of the cation. [199].
Hydrogel beads are fabricated by dropping either the polymeric solution or the
nanocellulose suspension into aqueous solution of polyvalent cations; since cations
diffuse into the polymeric drops, the three dimensional ionically cross-linked network
is formed (see Fig. 3.9). This method is widely used due to its simplicity; furthermore
it allows microencapsulation (active ingredients and cells, food and cosmetics)
without using toxic ingredients and with negligible products degradation, since the
encapsulation of those materials is performed under mild environment.
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Fig. 3.9: Schematic of the NC hydrogels formation through ionotropic gelation: the beads are formed
by dropping the NC suspension in a salty aqueous solution; the electrostatic interactions
between negatively charged NC and the salt cations allow the formation of NC hydrogels.
3.3 Results on CFZ and BC release from NC
hydrogels
3.3.1 Preparation of NC suspension and NC hydrogels
fabrication
I prepare NC suspensions by slightly modifying the procedure proposed in [186]. NC
is oxidized at alkaline pH and room temperature: 1 g of never dried cellulose pulp is
suspended in 100 mL H2O and stirred for 1h; then 0.1 g of NaBr, 3 mL of 1.75 M
NaClO (3.5 mmol per gram of cellulose) and 16 mg TEMPO are added to the slurry
under vigorous stirring. I maintain the pH of the solution in the interval 10.5-11
by adding 1 M NaOH until pH stabilises to a constant value. Then I thoroughly
wash the slurry with DI H2O, to bring it to neutral pH. Using an ultrasonic tip, I
sonicate 50 mL of the slurry at 20 kHz and 100 W for 15 min (Bandelin Sonopuls
HD2200, tip with a diameter of 13 mm in diameter). Finally, I concentrate the
sonicated solution with a rotary evaporator (Heidolph, Schwaback Germany) to a
final concentration of TEMPO-oxidized NC of 10 mg/mL.
I prepare different dispersions of CFZ and BC using either TW20 or TW80 surfactants
(composition details are given in the following sections). These dispersions are
homogenized using a vortexer, then 1.5 mL of NC suspension (10 mg/mL) are added
to each dispersion and mixed again.
I fabricate the gels by ionotropic gelation: the beads are formed by dropping
the dispersions in aqueous solution of 1M CaCl2 or 1M AlCl3. Since I know the
dispersions composition and I weight the extruded dispersions (using an analytical
balance), I calculate the amount of the various components in each bead.
I monitor the release either in H2O or in ETOH. Albeit water is the biologically
relevant solvent, the release kinetics cannot be easily monitored at sink conditions
in it (due to extremely low molecule solubility). Thus I perform the experiments in
water to demonstrate that surfactant co-loading is a successful strategy to increase
the drugs solubility; yet I used ETOH as model solvent as it allows to monitor the
dynamic of both CFZ and BC release on a reasonable time scale, with good S/N
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ratio and at sink conditions. In fact, ETOH is moderately polar and it exchanges
easily with the H2O in the hydrogels and both molecules are soluble in it (CFZ 0.2
mg/mL and BC 0.03 mg/mL).
To monitor the molecule release, at time t=0, 5 loaded beads are immersed in a
known amount of solvent (ETOH or H2O at pH=6.5) in a plastic tube and placed on
a shaker.
The solubility of both CFZ and BC in the two investigated solvents differ by orders of
magnitudes, so that I have to adopt two diverse strategies to monitor their release:
• in ETOH: at predetermined time intervals I substitute the entire volume of the
release medium and I analyse spectrophotometrically the amount withdrawn;
• in H2O : the limited solubility prevents to perform the experiments at sink
conditions. Thus I record the release within a finite release volume (4 mL),
up to saturation (at specified time intervals I analyse spectrophotometrically
an aliquot of the released medium and then I placed it again in the tube).
All the experiments have been performed at least in triplicate.
3.3.2 Release of CFZ from NC hydrogels
Here below I report the results obtained investigating the CFZ release from NC
hydrogels both in ETOH and H2O. Since I note that CFZ shows complex spectral
behaviour in presence of cations, before describing the release experiments, I clarify
how this molecule interacts with salts and how the CFZ absorption spectra are
affected by such interactions.
Finally, I evaluate the ex-vivo CFZ permeability, using freshly excised rat intestinal
mucosa as a model membrane (this work has been done in collaboration with the
group of Prof. Andreas Bernkop-Schnürch of the University of Innsbruck).
Interactions of CFZ with cations
During the release experiments I notice that the CFZ spectra show a significant
drift that needs to be controlled, thus I investigate the reason of this spectral shape
dynamic and the results are reported in this section.
To perform CFZ release in ETOH, I prepare gels with different amount of CFZ per
bead, as reported in Tab. 3.1.
The spectrum of pure CFZ dissolved in ETOH is shown with dotted line in Fig.
3.10A. The spectra of the CFZ released from diluted samples (A,B and C) have a
red-shifted lineshape with the maximum that moves from 451 to 484 nm (as an
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Tab. 3.1: Hydrogels compositions for CFZ release experiments in ETOH.
Sample CFZ per bead [nmol] CFZ [mg] ETOH [µL] TW20 [mg]
A 10 0.24 150 100
B 55 1.19 150 100
C 490 10.67 150 100
C0 480 10.2 240 0
D 2935 65 150 100
Sample A and B are obtained by dilution from sample C.
Fig. 3.10: A) Absorption spectrum of CFZ dissolved in ETOH (dotted line) and CFZ relese spectra
from sample C acquired at different time (continuous lines); B) CFZ released spectra from
sample D acquired at different time.
example, continuous lines of Fig. 3.10A reports the spectra obtained from sample
C at different times during the CFZ release). On the other hand the spectrum of
CFZ released from the most concentrated sample (D) is characterized by a spectral
dynamics that modifies the CFZ spectra with time: as reported in Fig. 3.10B the
spectrum starts from a red-shifted and broadened shape and then it recovers that
of the pure CFZ dissolved in ETOH. I can exclude any role of the surfactant in this
spectral modification, in fact the CFZ released from gels prepared without TW20
(sample C0) shows the same color-changing phenomenon while the spectrum of CFZ
dissolved in ETOH and TW20 does not.
I perform two experiments in solution (i.e without the hydrogels) to further inves-
tigate this color-changing phenomenon.
• I prepare a solution of 9.3 µM CFZ with 9.3 µM CaCl2 solution in ETOH and
I monitor over time its spectral shape. As reported in Fig. 3.11, initially the
spectrum has the same shape as that of CFZ in ETOH (absorption maximum at
451 nm); then it bathochromically shifts. An isosbestic point is clearly evident
at 470 nm and after 48 h (i.e. at equilibrium) the absorption maximum is
detected at 481 nm.
• I prepare 47 µM CFZ in 2:100=H2O:ETOH solutions with different salt concen-
trations in the range from 19.6 nM to 19.6 mM, using both CaCl2 and AlCl3.
I wait 50 h to allow each CFZ solutions to equilibrate. The acquired data are
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reported in Fig. 3.12: lineshape varies accordingly to salt concentration and
presents an isosbestic point at 470 nm.
Fig. 3.11: Absorption spectra of CFZ dissolved in ETOH with CaCl2 acquired at different time; the
spectra overlap at the isosbestic point (at 470 nm).
CFZ is a weak base and, in aqueous environment, exists under two forms: cationic at
low pH and unprotonated at higher pH. The two forms have different absorption
spectra and the system presents a clear isosbestic point at about 470 nm [25, 200,
201]. I note that the spectral shape of the cationic CFZ in aqueous medium is the
same of CFZ in ETOH added with CaCl2/AlCl3, while the spectrum of the uncharged
CFZ in aqueous solution resembles that of CFZ dissolved in ETOH. As reported in
[202], a similar spectral modification is observed by adding glacial acetic acid to a
CFZ solution in CHCl3.
A plausible hypothesis is that the observed spectral variation is due to coordination
between CFZ and cations. I try to obtain the CFZ-cations association/dissociation
constants, following the approach used in [203], but the complex dynamics of
solvation prevents me from obtaining the equilibrium constant between the CFZ
Fig. 3.12: Spectra of CFZ dissolved in ETOH with different amount of A) CaCl2 and B) AlCl3; the
spectra overlap at the isosbestic point (at 470 nm).
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and the ions. Thus I estimate the CFZ-cations K0.5 constants, defined as the salt
concentration inducing the 50% of the spectral variation.
I perform this analysis for both Ca2+ and Al3+; I correct each spectrum by removing
the baseline using a spline function and I fit it with two gaussian functions using
the following formula:
y = A1 · e
−( w−c1
d1




where y is the measured Abs, w the wavelength, while A, c and d are usual gaussian
parameters (amplitude, center and width; these parameters are treated as free
during the fit). Two examples of this analysis performed with Al3+ are reported in
Fig. 3.13.
Fig. 3.13: Spectrum of CFZ in 19.6 nM (top panel) and 19.6 mM of AlCl3 (bottom panel). Left
panels report the experimental data (black dotted line) with the fit curve (green line);
right panels show the two gaussian contributions (red and blue lines) superimposed to
the experimental data (black dotted line).
Fig. 3.14 shows the normalized amplitude (A) of the two gaussian functions versus
the log10 of the salt concentration. The K0.5 values for AlCl3 and CaCl2 are about
10 and 200 µM, respectively. The same values are obtained considering either the
decrease in amplitude of the left gaussian or the increase of the right one. Since the
spectra acquired at salt concentration greater than 9800 µM have the same spectral
shape in both salts, I assume that, at this concentration, CFZ is fully solvated by
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both cations. Using 47 µM concentrated CFZ solutions this saturation happens at
about 20 µM and 10000 µM in the case of AlCl3 and CaCl2, respectively. Since the
CFZ-cations interactions are electrostatic and characterized by a limited chemical
specificity, it is reasonable to assume that more Ca2+ ions are needed to solvate a
single CFZ, while one Al3+ interacts with more CFZ molecules.
Fig. 3.14: Normalized amplitude (A) of the gaussian function centered around 455 nm (left panel)
and 510 nm (right panel) versus the log10 of the salt concentration for both AlCl3 (magenta-
squares) and CaCl2 (green-circles); lines are guide for the eyes.
The dynamic of the CFZ spectra reported in Fig. 3.10 can be described considering
that inside the as-formed gel beads there is an excess of salts [204]. Thus in
samples with lower CFZ concentration (A, B and C), all the released molecules are
coordinated to CaCl2; on the other hand for sample D, the loaded CFZ concentration
is so high that the excess of salt inside the gels is not enough to coordinate all the
loaded molecules. In this case the first released CFZ are coordinated to the ions (red
line in fig. 3.10B), but as time goes by, more and more CFZ are released unbound
and the spectra of the released molecules revert to that of the CFZ in pure ETOH
(black line in fig. 3.10B).
Kinetics of CFZ released in ETOH
CFZ release experiments in ETOH have been performed using the same samples
reported in Tab. 3.1 and, if not otherwise specified, the gels have been fabricated with
CaCl2. The fact that, in presence of salts, CFZ exists under two forms (coordinated
and uncoordinated), allows to quantify the total amount of released CFZ using the
isosbestic point, whatever the form present in solution [25]. From the data shown
in Fig. 3.11, I calculate the molar absorption coefficient at the isosbestic point, that
is 25900 L·mol−1·cm−1.
Fig. 3.15A shows the normalized release profiles fitted with the the empirical 1st-
order model (see Eq. 1.13). This model fits rather well the experimental data
(with R2 of 0.998, 0.995, 0.996 and 0.988 for samples A, B, C and D, respectively).
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Fig. 3.15: A) Normalised CFZ release profiles in ETOH from sample A (red-triangles), B (black-
circles), C (green-squares) and D (blue-crosses) fitted with the empirical 1st-order model
(dotted lines); the inset shows a zoom up to 5 h. B) k coefficient values as a function of
the amount of CFZ per bead; errorbars are prediction bounds and line is a guide to the
eyes.
Looking at the value of the k coefficients (see Fig. 3.15B) it seems that an increase in
the amount of loaded CFZ, gives rise to slower release kinetics. Actually, it should be
remembered that k is expressed in time−1 [h−1], so that it does not give information
about the molecular flux (unless the beads have the same size and shape and are
loaded with the same amount of drug). Such information can be obtained looking
at the absolute values of the release (see Fig. 3.16, left panel) and their 1st order
derivative (see Fig. 3.16, right panel): the higher the loading values, the larger
the molecular flux, meaning that the limiting step for the CFZ release is not the
molecular diffusion from the bead surface to the solvent. To better understand the
parameters that play a role in the CFZ kinetics, I compare the release from sample
C (about 485 nmol per bead, green dotted line in Fig. 3.17, left panel) with the
release of the last 485 nmol from sample D (red continuous line in Fig. 3.17, left
panel). Assuming the drug homogeneously dispersed in the gel beads and the same
dynamic of CFZ aggregates dissolution, I would have expected the same release
profile. Actually, as reported in the inset, despite the amount of CFZ per bead is
the same, different kinetics are observed; in particular the release of the last CFZ
Fig. 3.16: Left panel shows the fit curves obtained with the empirical 1st order model as a function
of time; right panel reports the 1st order derivative of the fit curves.
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Fig. 3.17: Left panel reports the fit curves of sample C (green dotted line) and D (blue dotted line);
red continuous line highlights the last part of the release from sample D, to be compared
with the release from sample C, as reported in the inset. Right panel shows the fit curves
of sample B (black dotted line) and C (green dotted line); red continuous line highlights
the last part of the release from sample C, to be compared with the release from sample B,
as reported in the inset.
molecules from sample D is slower with respect to the same amount of CFZ from
sample C. I obtain an analogous result when comparing the release from sample B
(black dotted line in Fig. 3.17, right panel) with the last part of the release from
sample C (red continuous line in Fig. 3.17, right panel). These different kinetics
can be due to a non homogeneous CFZ distribution inside the gels when considering
the last part of the release (e.g. the external shell of the bead of sample D has a lower
CFZ concentration with respect to that of sample C), but also to the formation of
different aggregates distribution (i.e. the number of aggregates and their dimensions
can change as a function of the drug loading).
To confirm the fact that the CFZ release is not diffusion limited, I use the well-known
power law model (see Eq. 1.14), taking into account the first 60% of the released
process: I find values of the exponent n (from 0.44 to 0.9) always greater than
the one predicted for fickian (i.e. diffusion limited) release from spherical beads
(n=0.43)[205]; moreover there is no clear dependence of n values from the amount
of CFZ initially loaded.
Since I believe that the presence of CFZ aggregates within the hydrogel and the
dynamics of their dissolution play an important role in the release kinetics, I try to
use also the model that consider suspensions (see Eq. 1.8). All the parameters in
Eq. 1.8 are known, except D and cs. Considering a fast exchange between ETOH
and H2O (qualitatively demonstrated in Fig. 3.18), I assume that the liquid phase is
constituted by pure ETOH, thus the only free parameter is D. This model is valid as
long as the drug concentration in the matrix largely exceeds its solubility. For this
reason, among the four tested samples, I can use only the two most concentrated,
since they have a reasonable amount of data to be fitted. The results are shown in
Fig. 3.19: red data are discarded from the fit, as for these points, the concentration
is below the CFZ solubility. Despite the model fits rather well sample C, it is evident
that it can not be generalised to higher concentrations (as it badly reproduces the
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Fig. 3.18: Pictures of NC gels after being immersed for 20 min in H2O (left panel) and ETOH (right
panel) and then drying in air for some hours. The fact that ETOH exchanges easily with
H2O is demonstrated by the shrinking of the beads once they are left to dry in air.
Fig. 3.19: Normalised CFZ release profiles in ETOH from sample C (left panel) and D (right panel)
fitted with the model that consider diffusion from suspensions (black dotted lines); red
data are discarded from the fit.
data of sample D). Since the experiments have been performed at sink conditions, the
saturation of the solution can not be the reason why this model does not describe the
CFZ release kinetics. I believe that mechanical/structural modifications in the gels
(e.g. swelling induced by the solvent exchange or inhomogeneous gel environment)
that give rise to a time- and space-dependent D.
The amount of CFZ estimated from absorbance measurements is compatible within
5% with the amount loaded into the beads, thus I demonstrate a quantitative release
of CFZ from NC hydrogels.
To obtain rate-controlled DDSs an interesting strategy is given by the use of hydrogels
with different mechanical characteristics. This can be achieved by tuning hydrogels
stiffness using different multivalent cations as crosslinkers during ionotropic gelation
[206]. I prepare gels using the same composition of sample C and either CaCl2 or
AlCl3 as crosslinker; then I monitor the drug release kinetics in ETOH. Fig. 3.20
reports the normalized release profiles fitted with the the empirical 1st-order model
(see Eq. 1.13). This experiment has been performed with gel beads containing the
same amount of CFZ, so that (differently from the dataset shown in Fig. 3.15) the
k values give information about the molecular flux. I find that the ratio kAl/kCa is
equal to 0.6: since Al-based hydrogels are stiffer than those formed using Ca2+, the
NC hydrogels formed using AlCl3 release the drug more slowly than CaCl2 gels.
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Fig. 3.20: Normalized CFZ release profiles in ETOH from CaCl2 (green-squares) and AlCl3 gels
(black-circles), fitted with 1st order model (dotted lines). The values obtained for k are
kAl= 1.1±0.1 h−1 and kCa= 1.8±0.2 h−1 (errors are prediction bounds).
Kinetics of CFZ released in water
In this section I demonstrate the use of NC hydrogel to increase the CFZ solubility in
water. To do so, I prepare gels with the same amount of CFZ (490 nmol for each
bead) that differ for both type and amount of surfactant, as reported in Tab. 3.2 (the
label assigned to these samples are (type of TW)-(amount of TW per beads [mg])).
Tab. 3.2: Hydrogels compositions for CFZ release experiments in H2O.
Sample CFZ [mg] ETOH [µL] TW20 [mg]
TW20-0 11.12 240 0
TW20-0.7 11.23 208 35
TW20-2.4 11.25 137 114
TW20-3.3 11.15 93 162
Sample CFZ [mg] ETOH [µL] TW80 [mg]
TW80-3.3 11.09 92 158
The absorption spectra acquired for the different samples and at different time have
the same spectral shape (an example is reported in Fig. 3.21, continuous blue line)
with an absorption maximum at 492 nm. The red-shift can be due to either CFZ
coordinated to CaCl2 or protonated CFZ (since the pHaqueous media < pKaCFZ=8.51
[24]). The facts that the spectra of CFZ released from gels with and without TW
have the same spectral shape and the absence of scattering suggest that TW is able
to solubilize CFZ without forming large micelles.
Fig. 3.22A shows the amount of released CFZ, that has been quantified using the
absorbance value at the isosbestic point.
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Fig. 3.21: Normalised spectrum of CFZ dissolved in ETOH (continuous black line) compared to the
normalized spectra of CFZ acquired during the release of CFZ in H2O (continuous blue
line) or in ETOH (dotted red line).
Fig. 3.22: A) CFZ release profiles in H2O from T-0 (green-stars), TW20-0.7 (blue-circles), TW20-2.4
(red-squares), TW20-3.3 (black-triangles) and TW80-3.3 (magenta-crosses); lines are
guide to the eyes. B) Linear relationship between the amount of CFZ released at the
plateaus and TW20 content per bead (the first saturation plateau is indicated by the blue
continuous line, the second one by the red dotted line).
After 24 h a plateau is reached and the concentration of CFZ released from hydrogels
without TW is only 0.48 µM (green-stars in Fig. 3.22A). On the other hand, gels with
TW20 release an amount of CFZ proportional to the surfactant concentration, as re-
ported in Fig. 3.22B (blue line). In the case of TW20-3.3, CFZ concentration reached
20.7 µM, i.e. the H2O solubility of CFZ is increased by 43 times (black-triangles
in Fig. 3.22A). Using the same amount of surfactant, but substituting TW20 with
TW80, the CFZ concentration can be further increase to 25.5 µM, i.e. 53 times the
CFZ H2O solubility (magenta-crosses in Fig. 3.22A).
After 24 h I substitute the release media and the CFZ restarts to diffuse from hydro-
gels until another saturation is reached (this experiment has not been performed
using TW80). Also in this case the amount of CFZ released at plateau (at 33 h) and
the quantity of TW20 loaded correlate linearly, as reported in Fig. 3.22B (red line).
Furthermore, the CFZ concentrations in the release media are much higher than its
solubility, suggesting that after 24 h inside the gels there are still TW20 molecules.
These two observations lead to the following alternative hypotheses:
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1. the presence of the plateaus is due to the fact that the maximum CFZ solubility
in a solution with TW20 is reached: by increasing the TW20 content inside the
gels, more TW20 will be present in the released media at equilibrium, so that
more CFZ is solubilized;
2. the presence of TW20 within the gels has an active role in increasing the mass
transport of CFZ from the gel to the aqueous solution.
Here below, I firstly report a simple model that supports the second hypothesis, and
then I will describe the experiment carried out to exclude the first one.
Assuming TW20 is free to diffuse, after 24 h it equilibrates both inside the gels and
in solution, thus hindering the release of other CFZ molecules; once the release
medium is substituted, TW20 restarts to diffuse from the gels and it solubilises other
CFZ molecules.
According to this simple model, I estimate the ratios TW/CFZ. I know that 5 gel
beads of the sample TW20-0.7, TW20-2.4 and TW20-3.3 contain 2800, 9800 and
13600 nmol of TW20, respectively. Each bead has a spherical shape (0.6 cm in
diameter), so the volume occupied by the 5 beads is 1.88 cm3. The first release has
been performed in 4 mL and, assuming the TW20 is free to diffuse, at equilibrium
(after 24 h) it will have the same concentration both in the gels and in the release
medium (1.88+4=5.88 mL). Since the volume of the release media is the 68% of
the total volume, the equilibrium concentrations of TW20 in the release media are
480, 1670 and 2310 µM. The same estimation can be done for the second release,
that has been performed with 5 beads in 3 mL: in this case the solvent volume
is 61% of the total volume and the TW20 concentrations in the release media, at
equilibrium, are 180, 640 and 890 µM. In Fig. 3.23 I report the released amount
of CFZ versus that of TW20 for the first and the second release and I fit the data
with a linear model (the black line is the fit of the first saturation, while the data
of the second plateau are fitted by the green line). The TW20/CFZ ratio in the
release media at equilibrium is given by the inverse of the slope: I find values of
111 (first release) and 218 (second release). Performing the same calculation for the
gels containing TW80 (considering the plateau reached after 24 h) I obtained that
TW80 concentration at equilibrium is 2130 µM, thus the TW80/CFZ ratio is given
by 2130/25.5=84.
To validate this simple model, I prepare saturated CFZ solutions in 23, 230, 1150
and 2300 µM of TW20 and 2100 µM of TW80. I mix them with a vortexer and, after
some hours, I centrifuge them (at about 15000 g for 5 min) to acquire the surnatants
absorption spectra. The CFZ concentrations (estimated at the isosbestic point) as a
function of surfactant concentrations are reported in Fig. 3.24. The amount of CFZ
in the surnatants containing 2300 µM of TW20 and 2100 µM of TW80 are 19.8 and
24.8 µM, respectively. These values are very close to the quantity of CFZ released
from the gels after 24 h (i.e. 20.7 and 25.5 µM). Furthermore, I fit the TW20 data
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Fig. 3.23: CFZ released after 24 h (black-triangles) and after 33 h (green-crosses) versus estimated
TW20 concentration at equilibrium; the black continuous line is the linear fit for the first
plateau, while that of the second saturation is the green dotted line.
Fig. 3.24: Amount of solubilised CFZ as a function of surfactant concentration (TW20 black-squares
and TW80 blue-circle) concentrations. The black dotted line is the linear fit of the data
obtained using TW20.
with a linear curve (red line in Fig. 3.24): from the inverse of the slope, I obtain
the ratio TW20/CFZ equal to 123. This value has to be compared with 111, obtained
from Fig. 3.23. Although the surfactant aggregation number strongly depends on
pH, ionic strength, presence of solvents and molecules inside the micelles, all the
obtained estimations are of the same order of magnitude (roughly 100) of TW20
and TW80 aggregation numbers in H2O [207–209].
At this point, I show the result that permits to exclude the hypothesis that the plateau
is due to the saturation of the CFZ-TW20 aqueous solution. In fact, I would have
expected that using gels without surfactant (i.e. TW20-0) and performing the release
in water containing 2300 µM of TW20, the amount of CFZ in the release media
would be about 20 µM. Actually, the CFZ concentration after 24 h is only 2.6 µM; this
very low value confirms that the surfactant diffusion from the gels is the driving
force for the CFZ delivery, as described in the model above.
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Permeability study of CFZ across rat intestinal membrane
The promising results obtained from the CFZ release in H2O suggest a possible
application of NC hydrogels as DDS. To verify this possibility I tried to evaluate the
CFZ permeability ex-vivo, using the rat intestinal mucosa as a model membrane and
EtOH as a model solvent. Initially I try to evaluate the permeation of CFZ released
in water from the gels, but the CFZ signal is below the instrumental detection limit,
even using the most concentrated solutions. For this reason I prepare CFZ alcoholic
solutions with and without TW20 (0.16 mg/mL CFZ + 3 mg/mL TW20 in EtOH and
0.16 mg/mL CFZ in EtOH) in order to evaluate the potential permeation-enhancing
effect of TW20 solvated CFZ through freshly excised intestinal mucosa. A piece
of intestine is mounted on Ussing-type chambers (Warner Instruments, LLC; 1125
Dixwell Avenue; Hamden, CT 06514, USA) with a surface area of 0.64 cm2 (see
Fig. 3.25). After an incubation of 15 min with PBS at pH=6.8 to properly wash the
intestine piece (as required by the typical protocol used pharmacists) I substitute the
PBS with ETOH in the acceptor compartment and I fill the donor chamber with CFZ
solution. At predetermined time points (0, 30, 60, 90, 180 and 360 min) I remove
100 µL from the acceptor and I immediately replaced them with fresh medium.
I use a multifunctional microplate reader (TECAN SPARK, Tecan Austria GmbH,
Grödig, Austria) to spectrophotometrically quantify the amount of permeated CFZ:
I measure the absorbance of the withdrawn samples at 470 nm considering the
molar absorption coeff at the isosbestic point.
The comparison of the drug permeation of solutions with and without surfactant is
reported in Fig. 3.26.
According to the acquired data the presence of TW20 increases by a factor 2 the CFZ
permeability. This result is very promising, since it demonstrates that the surfactant
co-loading increases both the CFZ H2O solubility and its permeability through the
intestinal membrane.
The permeability quantification of such insoluble molecule using the aqueous release
media requires optimize experiments that will be the subject of future investiga-
tions.
Fig. 3.25: Schematic of the Ussing-type chamber.
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Fig. 3.26: Ex-vivo CFZ permeation across intestinal mucosa during 6 h using solution with (red-
circles) and without (black-squares) TW20; lines are guide to the eyes.
3.3.3 Release of BC from NC hydrogels
Considering the good results obtained by the release of CFZ from NC hydrogels, I
performed similar experiments using BC, too. In this section I report the results
obtained using both ETOH and H2O as release media.
Kinetics of BC released in ETOH
Tab 3.3 reports the composition of the different prepared gels.
Tab. 3.3: Hydrogels compositions for BC release experiments in ETOH.
Sample BC per bead [nmol] BC [mg] ETOH [µL] TW20 [mg]
A 10 0.27 148 100
B 55 1.35 148 100
C 460 11.68 148 100
Sample A and B are obtained by dilution from sample C.
The spectra of BC released from the gels have the same shape as that of BC dissolved
in ETOH. Differently from the CFZ, BC molecules do not interact with cations, as
there are no spectral variation in solutions with and without salts dissolved. To
quantify the total amount of released BC, I use the value of the absorbance maximum
in ETOH (452 nm) and a molar absorption coefficient of 144000 L·mol−1·cm−1. The
normalized release profiles fitted with the empirical 1st-order model (see Eq. 1.13)
are shown in Fig. 3.27. The amount of released BC estimated from spectrophoto-
metric measurements and that loaded into the beads are compatible within 6%, thus
a quantitative release of BC from NC hydrogels is demonstrated.
Since the beads are not loaded with the same amount of BC, the k coefficients give
no information about the molecular flux, but I can compare these k values with those
obtained from gels loaded with the same CFZ concentration. As reported in Tab.
3.4 it is evident that the BC kinetics are much slower than those of CFZ. The slower
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Fig. 3.27: Left panel shows the normalised BC release profiles in ETOH from sample A (red-triangles),
B (black-circles) and C (green-squares) fitted with the empirical 1st-order model (dotted
lines); right panel reports a zoom up to 120 h.
BC kinetic does not depend on its lower solubility in the release medium (in ETOH
the solubility of BC is 0.03 mg/mL vs 0.2 mg/mL of CFZ). In fact, I perform releases
of BC in acetone (BC solubility = 0.2 mg/mL) and I compare the obtained release
kinetic with that of CFZ in ETOH (see Fig. 3.28). To quantify the amount of released
BC I use the maximum absorbace value (at 454 nm) and ε=140000 L·mol−1cm−1.
Although BC in acetone and CFZ in ETOH have the same solubility and about the
same molecular weight (537 vs 473 gr/mol), their very different shapes (see Fig.
1.2), the fact that they interact differently with the gel components and the different
solvent viscosity give rise to diverse rate releases (kCFZ-ETOH = 1.8 ± 0.2 h−1 vs
kBC-acetone = 0.15 ± 0.02 h−1).
Tab. 3.4: k coefficients obtained fitting the data of CFZ and BC release in ETOH; errors
are prediction bounds.
CFZ per bead [nmol] BC per bead [nmol] kCFZ [h−1] kBC [h−1]
10 10 5.1±0.7 0.32±0.03
55 55 4.5±0.7 0.13±0.02
490 460 1.8±0.2 0.014±0.001
Fig. 3.28: Normalised CFZ release profile in ETOH (green-crosses) fitted with the empirical 1st-order
model (dotted lines).
74 Chapter 3 Nanocellulose
Kinetics of BC released in water
To demonstrate that the co-loading of BC and surfactants inside the NC hydrogels
is a successful strategy to increase the BC solubility in water, I prepare gels with
the same amount of BC (430 nmol for each bead) containing either TW20 or TW80
(details about compositions are given in Tab. 3.5).
Tab. 3.5: Hydrogels compositions for BC release experiments in H2O.
Sample BC [mg] ETOH [µL] TW20 [mg]
TW20-BC 11.01 93 162
Sample BC [mg] ETOH [µL] TW80 [mg]
TW80-BC 11.24 88 162
Absorption spectra have all the same spectral shape (an example is shown in Fig.
3.29A), with an increasing contribution due to scattering at wavelengths below 500
nm. To quantify the amount of BC released, I used the peak at 458 nm (assuming
ε=144000 L·mol−1cm−1 and a negligible scattering at this wavelength) and the
data are reported in Fig. 3.29B. A control experiment with BC-hydrogels without
surfactants (11 mg BC and 153 µL ETOH) shows no signal in the region characteristic
of BC after 24 h of release time.
Fig. 3.29: A) Normalised BC spectrum acquired during the release of BC in H2O; red arrow indicates
the peak at 458 nm. B) BC release profiles in H2O from TW20-BC (red-circles) and
TW80-BC (blue-squares); lines are guide to the eyes.
To investigate the reason of the scattering in the UV part of the spectrum, I prepare
aqueous solution of TW20 and TW80 at concentration higher than their critical
micelles concentration. Since the acquired spectra are flat, I hypothesize that the
scattering is due to larger surfactant micelles containing BC. To verify this hypothesis
I have to destabilize the micelles and extract the BC using the solvent extraction
method (to note that such experiment requires a large number of different samples
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as, for each release point, 3 samples are needed to perform the experiments in
triplicate). At predetermined time, 1 mL of each release medium is added to 2 mL
of hexane (BC solubility: 0.6 mg/mL [160]). To extract the BC, I mix the solutions
with a vortexer and I use an ultrasound treatment to disrupt the micelles (5 min
at 400 W), finally I centrifuge (at about 5200 g for 3 min) to separate the two
phases. The absorption spectra of the aqueous phase do not show any signal in
the BC region; on the other hand, the absorption spectrum of the organic phase
(reported in Fig. 3.30A), clearly shows the typical BC spectrum. The amount of
BC in this phase (estimated using the maximum absorbance value at 450 nm and
ε=140000 L·mol−1cm−1) is reported in Fig. 3.30B. To note that the scattering is
highly reduced in these surnatants, supporting the idea that BC is contained within
micelles disrupted upon sonication. From both analyses (see Fig. 3.29B and 3.30B)
the amount of BC released from gels containing TW80 is higher with respect to that
release when TW20 is used. The high SD in the BC concentrations obtained using
the solvent extraction method are due to the fact that the different components of
the suspensions (BC, H2O, hexane and surfactant) do not always mix in the same
manner (as an example, I can not exclude that either some hexane is entrapped
in surfactant micelles in H2O, leading to an effective increase in the amount of BC
released or some BC remains inside the micelles in H2O, so that the quantity of BC is
underestimated).
As in the case of CFZ, I try to form BC-TW micelles in H2O preparing saturated
solutions of BC in either 2300 µM or 2100 µM of TW20 and TW80. I mix them
with a vortexer and sonicate (up to several minutes at 400W). Finally, I centrifuge
(about 15000 g for 5 min) them to acquire the surnatants absorption spectra; in
none of the cases I see the BC absorption spectra, not even by adding ETOH and
NC to these saturated solutions.
These results are quite surprising, as they suggest that the BC released from the gels
is entrapped in micelles that form only thanks to NC hydrogels. Probably, when both
BC and TW are loaded within the hydrogels they are forced to orient themselves in
Fig. 3.30: A) Normalised spectrum of the BC in the organic phase. B) Amount of BC released in H2O
from gels with TW20 (black-crosses) and TW80 (green-triangles) estimated by the solvent
extraction method; lines are guide to the eyes.
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such a way that eases the formation of TW micelles entrapping BC, while when TW
molecules are free to move in the aqueous environment, the formation of micelles
without BC is favoured.
With these experiments I demonstrate that the co-loading of BC and surfactants is a
successful strategy to solubilize BC in H2O and that the formation of solid dispersion
in the NC hydrogels is crucial to obtain BC-TW micelles.
3.3.4 Storage of CFZ and BC in NC hydrogels
The promising results obtained releasing both the hydrophobic molecules in H2O
suggest to verify if the NC hydrogels carriers protect the molecules from degradation,
too.
I prepare both CFZ and BC loaded hydrogels using TW20 and TW80 (details about
composition are given in Tab. 3.6).
Tab. 3.6: Hydrogels compositions used in the storage experiment.
Sample CFZ/BC [mg] ETOH [µL] TW20/TW80 [mg]
TW20-CFZ 5.3 61 196
TW80-CFZ 5.3 60 192
TW20-BC 5.3 61 196
TW80-BC 5.2 60 192
The loaded beads have been stored in plastic tubes in the dark at room temperature
for 45 days and then I perform the release in ETOH.
The quantity of released CFZ from gels quantified from spectrophotometric mea-
surements is 98%±6 (TW20) and 105%±6 (TW80) of that loaded into the beads,
thus I demonstrate that a quantitative release of CFZ from NC hydrogels can be
obtained even after 45 days. Surprisingly, the amount of BC released from the NC
hydrogels after 45 days of storage is 86%±5% and 92%±6% of the loaded one, in
the case of TW20 and TW80, respectively. Thus, despite BC loaded into the gels is
immersed in aqueous environment, the surfactant protects this delicate drug from
degradation over quite long time scale. Tab. 3.7 compares these results with those
reported in Sec. 2.2.8 and in Appendix; it demonstrates that NC beads are very
promising BC carriers able to protect this delicate molecule and they heavily slow
down its degradation.
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Tab. 3.7: Amount of non-degraded BC (relative to that at t=0) after 15 and 45 days under
various conditions; all samples have been kept in the dark and, unless otherwise
specified, at room temperature.








gels with TW20 86±5
gels with TW80 92±6
∗ These data are reported without errors since they are the results of solution absorbance
measurements and the errors are negligible.
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4Conclusions
In this thesis I investigated the use of two nanostructured materials as carriers for
hydrophobic drugs. The interest in these molecules is related to the fact that an
estimated 40% of approved active compounds and nearly 90% of the developmental
pipeline drugs are poorly water soluble and they need special care both to design
carriers able to load and release them, as well as strategies to overcome biological
barriers and to render these ingredients bioavailable.
In this work I used BC and CFZ, which are two of the most difficult molecules to
solubilize in water [210]. I chose BC for its truly non polar structure that permits
to build a model system to investigate non polar interactions between the carrier
surface and the drug. CFZ has been used as an alternative hydrophobic molecule:
it is more chemically stable and slightly more soluble than BC in water.
In literature there is a plethora of publications on DDSs for hydrophobic molecules,
but the large amount of different drug, types of carriers and release media make
difficult a direct comparison between the results obtained in this thesis with those
published. Regarding the choice of the release medium, the tests are often carried
out in simulated fluids (whose composition varies from work to work [211]) and
there are also researches in which the solubility in water is actually evaluated with
a non negligible alcohol percentage [32]. I used either ETOH or water as release
medium and I did not perform the experiments in buffers, since the solubility of
the molecules (in particular when ionizable groups are present) and the carriers
behaviour (e.g. gel swelling) are affected by pH and ionic strength, so that I decide
not to introduce such parameters in these preliminary studies.
Initially I investigated the use of Psi as nanoporous carrier. This material is actively
studied for DD applications as demonstrated by the bibliometric data reported in Fig.
4.1 showing the steady increase in both citations and publications. The interest in
Psi as DDS arises from the several favourable characteristics it owns, in fact Psi:
1. can be prepared with huge specific area and porosity, thus it can load large
amount of active compounds compared to its weight;
2. is biodegraded by the human body and shows no toxic effects;
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Fig. 4.1: Bibliometrics of Psi used as DDS.
3. its surface chemistry is (quite) well known and it allows for a large number of
functionalization methods that are exploited to optimize its use and to render
it compatible with the cargo;
4. might protect the loaded compounds against photo-degradation (as it highly
absorbs UV-VIS radiation)
5. its pores can be closed (after the loading) to create core-shell devices prevent-
ing an untimely release of the cargo; furthermore the core-shell structure can
be designed to obtain stimuli-responsive materials;
6. can be reduced to microparticles that are readily uptaken by human cells
without adverse effects, thus the drugs can be effectively released within
cells;
7. is a photoluminescent material, allowing the microparticles tracking inside
the cells without the need of molecular tags.
There are plenty of nanoporous materials to which Psi can be compared to: from
polymers to metal-organic-framework, from carbon to semiconductors based. Most
of these materials either are based on fancy, not-too-common elements, or they are
not bio-compatible (e.g. Materials Institute Lavoisier (MIL)-100 and MIL-101 have
a huge surface area but contain toxic Cr ions). Thus, the comparison with porous
carriers state-of-art for DD is then limited to silica-based material, as they are among
the inorganic materials with the largest possibility to end up in real DD applications.
Silica-based carrier have high chemical stability and good biocompatibility; their
well known chemistry permits to tune their synthesis to fabricate well controlled
and hierarchical structured porous carriers. The most commonly investigated are
based on MCM-41, MCM-48, SBA-15, SBA-16 and on mesoporous silica nanopar-
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ticles (MSN). After the seminal work on the use of MCM-41 to release ibuprofen
[212], several of publications reported on the advances of using this platform for
DD. Despite their different structures, in some works Psi and MSN achieve a similar
drug loading efficiency of up to 30 % w/w, even when dealing with hydrophobic
compounds [213, 214]. In other publications much larger loading capacities are
reported (greater than 50% w/w) [215].
I loaded Psi with about 6 mg/g of drug per mass of Psi, that corresponds to 0.6%
w/w, a value that is orders of magnitude lower with respect to that reported in the
previous cited works. Actually, since I was interested in investigating the surface
interactions between BC and the pores surface, the structure of Psi samples was not
optimize to load large amount of drugs. Thus, a comparison with the state-of-art
results of Psi DDs is not fair and an order of magnitude improvement is foreseen
by simply optimizing the samples porosity and by using poorly soluble molecules
with polar groups. Moreover, given the non polar structure of BC, the drug loading
efficiency (that is often considered as one of the key parameter of DDSs) would
not give a real indication of the Psi DDS performance. Furthermore, despite the
large number of previously mentioned advantages, I discovered that Psi does not
perform well as carrier for hydrophobic molecule such as BC. The experiments
demonstrated that Psi stimulates BC degradation (rather than prevents it) even if
its surface is carefully passivated. Although I could not unveil the chemical paths
of these reactions, I observed that BC degradation is faster within Psi than in air
or in liquid solvents. Probably, its chemical degradation is due to interface redox
reactions that oxidize BC. Furthermore I noticed that, during the release experiments,
BC tends to nucleate on Psi surface forming aggregates whose dissolution is much
slower than the BC molecules release, thus they negatively impact on the control
over the drug release. The nucleation event is not influenced by the chemical state
of the Psi surface (as it happens on both hydride and oxide terminated samples),
but it strongly depends on the details of the loading process. I hypothesized that
these BC aggregates are the result of heterogeneous nucleation promoted by the
large surface energy of silicon nanostructures. Since I found that the SDs of the
release experiments precisely correlates with the aggregates formation, I proposed
to use the SD as a method to determine the formation of heterogeneous nuclei on
nanostructured surfaces, in alternative to the commonly used "induction time".
During the last year of the PhD, I started to investigate a different type of carrier: NC
hydrogels. To the best of my knowledge, this is the first work on pure NC hydrogels
for BC and CFZ release.
The use of NC for the release of hydrophobic compounds is an unexplored research
field: there are only two publications on the use of modified CNC [216, 217] and no
work has been published about pure NC hydrogels. Even if considering hydrogels
in general (i.e. not necessarily made of NC) there are few publications about their
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use to deliver hydrophobic therapeutics (only about 250 works are listed in "Scopus"
database using the keywords "hydrogel" and "hydrophobic drug"); this is due to their
high water content that hinders the encapsulation of poorly soluble molecules. To
overcome this limit, the drug is often encapsulated in nanocarriers such as liposomes
or polymer nanoparticles, which are then incorporated into hydrogels. This method
is quite time consuming (some carriers preparations need up to few days [218]) and
the release is seldom complete, possibly due to the entrapment of the nanocarriers
within the hydrogels [219].
In this thesis I demonstrated that BC and CFZ can be loaded in NC hydrogels using a
very fast method (i.e. ionotropic gelation). Initially I studied how CFZ is released
from NC gels in ETOH. Although CFZ shows complex interactions with cations and
its spectrum changes substantially upon solvation in salty solutions, the presence
of a clear isosbestic point allowed me to quantify the amount of molecules released
whatever the CFZ form present in solution. I obtained promising results as I was able
to load up to 30% w/w (on dry basis) of CFZ within NC gels beads and to release it
quantitatively. A similar CFZ loading efficiency has been obtained using hypromel-
lose acetate succinate nanoparticles [27]. To note that drug loading capacities up
to about 70% have been reported for non NC-based hydrogels loaded with curcumin
and doxorubicin [220, 221]. Furthermore, I showed that NC hydrogels do not pose
heavy issues to the release of lipophilic drugs, provided that a suitable surfactant
(I used TW20 and TW80) mediates the molecule solvation and its subsequent re-
lease into aqueous media. The use of TW20 inside chitosan gels has been very
recently reported to increase the curcumin solubility in simulated gastric medium
[8] (there are no publications about CFZ relelase from hydrogels to compare with);
the authors demonstrated that the release of curcumin increased from 0.21% to
54.85% by increasing the TW20 concentration. These results are difficult to compare
with those obtained by me, both because the tested molecule, release medium and
hydrogels composition are different and because I did not optimize the amount of
CFZ loaded within the gels (which is in large excess) vs the amount of surfactant.
Yet I demonstrated that, with the investigated gel compositions, the CFZ water
solublity increases by 43 and 53 times using gels with TW20 and TW80, respectively.
Finally, I tried to quantify the permeability of the CFZ released from NC gels through
animal intestine membranes, but its quantity was below the instrumental detection
limit; such characterization requires the design of ad-hoc experiments and might
be a matter of further investigation.
Considering the good results obtained using CFZ, I investigated also the possibility
to release BC from the same type of hydrogels. I found that it can be quantitatively
released from gels in ETOH and, more interestingly, the BC solubility in water can
be increased if it is released in aqueous media from hydrogels (reaching concen-
trations of 0.27 µg/mL and 0.43 µg/mL using TW20 and TW80, respectively). In
fact control experiments made by direct dissolution of BC in water with surfactants
produced no BC solvation. These results suggest that BC is efficiently solvated by
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the surfactant within the hydrogel and before its release. Finally, I noticed that NC
gels protect this delicate molecule from degradation much better than its storage
in freezer or in organic solvent, making these carriers interesting for DD.
As far as I know, this is the first work that investigate hydrogels for CFZ release, while
concerning BC hydrogels, only a BC nanoemulsion encapsulation in alginate-based
hydrogel beads has been reported so far [222]. The authors demonstrate that the
BC stability is enhanced when the nanoemulsion is encapsulated in 500 µm hydrogel
beads, yet its biodisponibility decreases.
The results I obtained are very promising and encourage the NC hydrogel optimiza-
tion to further improve the performance of this type of carrier. In particular a finer
optimization of the hydrogels composition could lead to a quantitative drug release
also in aqueous media as well as to increase the water solubility of these compounds,
possibly to achieve results similar of those reported with other type of carriers. For
instance, BC solubility can reach 100 µgr/mL encapsulating BC in lipid nanoparticles
[223] and a further improvement can be obtained with BC emulsions (up to 0,3
mg/mL) [224]. Concerning CFZ, it has been reported that the use of hypromellose
acetate succinate, lecithin and zein nanoparticles allows to increase from 50 to 90
times the CFZ solubility in gastric fluid [27]. Try to achieve these higher solubility
values using the NC hydrogels can be fruitful since the fabrication of these carriers is




Homogeneous and heterogeneous nucleation
Nucleation is the first thermodynamically driven step that led to the formation of
a new phase with lower free energy. There are two types of nucleation: in the
homogeneous one the nucleus is formed in solution, while heterogeneous nucleation
occurs at preferential sites, such as phase boundaries, surfaces or impurities. In this
section I briefly report the thermodynamic basis of both homogeneous [225] and
heterogeneous nucleations [226].
Homogeneous nucleation
According to the classical nucleation theory (that treats the microscopic nucleus as
if it is a macroscopic droplet), the free energy (∆Ghom) of the new phase can be
written as the sum of a term proportional to its volume and a term proportional to





3∆GV + 4πr2σ (4.1)
where ∆GV is the difference in free energy per unit volume between the thermody-
namic phase in which the nucleation is occurring and the nucleating phase, while
σ is the surface tension of the interface between the particle and its surroundings.
Since the first term is negative and scales with r3, while the second is positive and
proportional to r2, for small r the surface term dominates, while at larger r the
volume term is predominant and the total free energy becomes negative (see Fig.
4.2).
At an intermediate value of r, the so called "critical radius" (r*), the free energy
goes through a maximum: the nucleus with a radius of r* is the least-probable, but
the addition of new molecules decreases the overall system free energy. Thus, ther-
modynamic fluctuations (perhaps near or above supersaturation regimes) might
promote the formation of stable nuclei.
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Fig. 4.2: Total free energy for homogeneous nucleation as a function of radius (black line): it is a
sum of the volumetric (blue line) and the surface free energy (red line).
Heterogeneous nucleation
Heterogeneous nucleation is more common than homogeneous, since the nucleus
formation on a surface often decreases the nucleation barrier with respect to ho-
mogeneous nucleation (see left panel in Fig. 4.3). As schematically depicted in
Fig. 4.3 (right panel), in this case there are 3 different phases (α, β and δ) and all
interactions α-β, α-δ and β-δ have to be considered.
Fig. 4.3: Left panel reports comparison of total free energy as a function of particle radius between
homogeneous (black line) and heterogeneous (magenta line) nucleation. Right panel shows
a schematic of the three phases of interest for heterogeneous nucleation; θ is the contact
angle.
Also in this case, the total free energy (∆Ghet) can be written as the sum of the




r3∆GV + Aαβγαβ + Aβδ(γβδ − γαδ) (4.2)
where ∆GV is the difference in free energy per unit volume between the two phases,
Aαβ and Aβδ are the areas of αβ and βδ interfaces, while γαβ, γαδ and γβδ are the
surface tensions of the interface between the different phases.
Eq. 4.2 can be written in terms of the contact angle θ:
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∆Ghet(r) =
πr3
3 [2 − 3cosθ + cos
3θ]∆GV + 2πr2(1 − cosθ)γαβ + πr2sin2θ(γβδ − γαδ)
(4.3)
Considering a droplet on a flat surface with fixed volume, the term γβδ − γαδ is equal




3∆GV + 4πr2γαβ] · [
2 − 3cosθ + cos3θ
4 ] (4.4)
Since first term in parenthesis is the ∆Ghom for homogeneous nucleation, then Eq.
4.4 can be rewritten as
∆Ghet(r) = ∆Ghom(r) · f(θ) (4.5)
where
f(θ) = 2 − 3cosθ + cos
3θ
4 (4.6)
To note that 0 ≤ f(θ) ≤ 1 and in particular if θ = π (f(θ) = 1) there is no surface
wetting, falling in the case of homogeneous nucleation and if θ = 0 (f(θ) = 0), the
wetting is maximum and there is no barrier for nucleation. As for homogeneous
nucleation, ∆Ghet(r) should pass through to a maximum: the critical radius can be
calculated by imposing d∆Ghet(r)dr = 0. According to this simple model, r* remains
unchanged for heterogeneous and homogeneous nucleation, while the volume
(due to the wetting angle affecting the shape of the nucleus) can be significantly
less in the case of heterogeneous nucleation. In the theory described so far, the
surface on which the nucleus grows is smooth; yet the critical size of the nucleus
and the energy barrier for its formation are influenced by surface roughness (e.g.
various studies demonstrate that fractal surfaces decrease the energy required for
nucleation to occur [227, 228]). Despite it is generally accepted that the energy
barrier for heterogeneous nucleation is lower with respect to homogeneous one, in
many practical cases, the mechanisms by which heterogeneous agents promote the
nucleation are still unclear [229].
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BC degradation
During the thesis work I observe that, despite stored as powder in freezer and
in the dark, BC quickly degrades. In the following sections I report the analyses
performed to try to investigate its degradation. Since I note a decrease of its
absorption coefficient with time (as reported in Fig. 4.4), I use ε to indicate the
extent of degradation.
Fig. 4.4: BC absorption coefficient as a function of time, fitted with a linear curve (red line).
The data in Fig. 4.4 are obtained by dissolving a known amount of BC in THF
and diluting 10 µl of this solution in 3 ml of ETOH; from the values of the ab-
sorbance maximum (at 452 nm) I calculate the ε using the well known Lambert-Beer
relation.
In the first section I report the analyses performed on BC powders with different
degradation extent, while in the second section I show the results of BC degradation
in two of the most used solvent for BC extraction (i.e. CHCl3 and THF).
BC stored as powder
I try to investigate BC powders with different degradation extent relaying on UV-VIS,
FTIR, RAMAN, NMR, HPLC and MALDI-TOF analyses. Despite the determination
of the products and reactions paths to them are out of the scope of this work, the
acquired data support the conclusions reported in [230].
NMR and HPLC analyses have been done in collaboration with Prof. Graziano Guella
at the Bioorganic Chemistry Laboratory of the Department of Physics, while MALDI-
TOF in collaboration with Prof. Giorgio Arrigoni at the Department of Biomedical
Sciences of the University of Padova.
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UV-VIS analysis Fig. 4.5 show the UV-VIS spectra of BC in ETOH (0.009 mg/mL)
with ε=144000, 30000 and 3500 L·mol−1cm−1. I exclude that the strong absorbance
decrease is due to the break of the π-coniugated BC structure, otherwise absorbance
spectra would shift to lower wavelength, as predicted by the empirical Fieser-Kuhn
rules for conjugated polyenes [161].
Fig. 4.5: UV-VIS spectra of BC at different degradation extent.
FTIR analysis The FTIR spectra of BC powder with ε=144000 and 3500 L·mol−1cm−1
are reported in Fig. 4.6. In the FTIR spectra of degraded BC there is a strong ab-
sorption band around 3500 cm−1 (consistent with the presence of hydroxyl group).
In the C-H stretching range (2800-3000 cm−1) and fingerprint region the peaks in
the degraded samples are very broad, hindering a fine spectral analysis. However, in
the degraded BC a signal at 1728 cm−1 is evident and it is compatible with the C=O
stretching.
Fig. 4.6: FTIR spectra of BC; the black arrow indicates the peak compatible with the C=O stretching.
RAMAN analysis I acquire the Raman spectra of BC powder with ε=144000 and
3500 L·mol−1cm−1; despite their very different extent of degradation, the acquired
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Raman spectra show no substantial differences (see Fig. 4.7). As reported in
[231–233], the dominant Raman modes of carotenoids are in the range 800-1800
cm−1: the peaks detected at 1008, 1156 and 1515 cm−1 can be assigned to in-plane
rocking modes of CH3 groups attached to the polyene chain coupled with C-C bonds,
stretching vibrations of C-C and C=C in the polyene chain, respectively. Concerning
the sample with ε=3500 L·mol−1cm−1, the absence of the peak associated to the
vibration of the C=O bond around 1700 cm−1 is probably due to the fact that its
Raman intensity is below the detection limit.
Fig. 4.7: Raw Raman spectra of BC.
NMR analysis The NMR spectra (normalized with respect to the CHCl3 signal) of 20
mM BC solution in CDCl3 using BC with ε=144000, 30000 and 3500 L·mol−1cm−1
are reported in Fig. 4.8. Degraded BC spectra show very broad signals, while sharp
peaks are present in the spectra of unaltered BC. This inhomogeneous broadening
can be due to oligomerization/polymerization reactions among BC molecules. The
signals at 9.5 (black arrow in Fig. 4.8) and around 8 ppm (magenta arrow in
Fig. 4.8) are present only in the degraded BC and can be assign to aldehydes (-H-
C=O) and aromatic groups respectively. The aldehydes groups can be formed only
in two cases: either due to the oxidation of a methyl groups or by the molecule
fragmentation. I speculate that aromatic rings form in the centre of the polyenic
chain, as the double bonds rearranged to form them. In the range 5-3 ppm (see inset
in Fig. 4.8) there are signals that can be associated to protons that are bound to C
sp3 linked to heteroatoms (probably oxygen).
HPLC analysis HPLC analysis has been performed using BC with ε=144000, 30000
and 3500 L·mol−1cm−1; the data acquired in the VIS region (at 450 nm) are reported
in Fig. 4.9A, while Fig. 4.9B shows the analysis in the UV range (at 245 nm).
The HPLC spectra acquired in the VIS range show BC signals at elution time of
about 40 min (see inset in Fig. 4.9A), whose intensities are strongly decreased with
increasing BC degradation (as already demonstrated by UV-VIS absorption). The
peak at 41 min is assigned to Cis-BC, while that at 42 min to Trans-BC; the peak
90 Chapter 4 Conclusions
Fig. 4.8: NMR spectra of BC in CDCl3.
between these two that is present in the non-degraded BC can be assigned to BC
isomers.
Concerning the analysis in the UV range, in addition to the BC signals at elution time
of about 40 min, I observe that for short times (see magenta arrow in Fig. 4.9B),
the UV signal is greater for the degraded BC (the highest peak around 1 min is due
to the solvent used for the elution). Since the analysis has been performed with an
inverse phase chromatographic column, these signals can be due to either oxidised
species or BC fragments.
Fig. 4.9: HPLC spectra of BC acquired in A) VIS and B) UV range.
MALDI-TOF analysis BC with ε=144000 (red lines in the following figures) and
ε=30000 (blue lines in the following figures) L·mol−1cm−1 have been analysed with
a MALDI-TOF spectrometer, both in positive and negative mode, by dissolving the
BC powder in 1:1=H2O:acetonitrile, 0.1% trifluoroacetic acid.
Fig. 4.10 reports the data acquired in negative mode: a peak at 535.4 m/z ([BC-H]−)
is present in both spectra; in the degraded BC spectrum appears a peak at 551.3
m/z, that is compatible to the oxygen presence ([M-H+O]−).
Concerning the analysis in positive mode (see Fig. 4.11), I note that at low laser
fluence only non-degraded BC can be detected (spectrum reported in Fig. 4.11A).
By increasing the laser intensity, some peaks appear in the low mass range, as
shown in Fig. 4.11B. These signals can be due to BC-fragments, probably generated
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by the laser fragmentation of some BC oligomers during the MALDI-TOF analysis.
At these laser fluence the degraded BC can be detected, too; yet in this case the
intensity of the signals in the low mass range is of the same order of magnitude
of that of BC itself (see Fig. 4.11C). Fig. 4.12 reports the zoom around 536 m/z
for non-degraded and degraded BC. The highest peak is at 536.4 m/z and can be
associated to the radical cation [BC]+. In BC-degraded spectrum other peaks appear
that can be assigned to oxidised BC species([M-H+O]+, [M-H+2O]+, [M-H+3O]+
and [M-H+4O]+).
Fig. 4.10: MALDI-TOF spectra of BC with ε=144000 (left panel) and 3500 (right panel) L·mol−1cm−1
acquired in negative mode.
Fig. 4.11: MALDI-TOF spectra acquired in positive mode of BC with ε=144000 L·mol−1cm−1 at
low laser fluence (upper panel), at high laser fluence (bottom left panel) and of BC with
ε=3500 L·mol−1cm−1 at high laser fluence (bottom right panel).
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Fig. 4.12: Zoom of MALDI-TOF spectra of BC with ε=144000 (left panel) and 3500 (right panel)
L·mol−1cm−1 acquired in positive mode.
BC dissolved in organic solvents
One of the main problem I face during the analysis of released drugs is the tiny
amount of molecules available. In a typical release experiment from Psi, I recover
few tens of nmoles of compound, thus the interactions and secondary reaction of
these molecules with solvent impurities become relevant. Here below I show the
results obtained by dissolving BC in CDCl3 and THF.
BC dissolved in CHCl3 I prepare a 1.5 mg/mL BC solution in CDCl3 stabilised with
silver wires (stab-CDCl3) (referred to "sol. X") and I dilute 5 µL of it in 2 mL of
both CDCl3 and stab-CDCl3. The BC spectrum is clearly visible when I dilute "sol.
X" in stab-CDCl3 (see Fig. 4.13, blue line), yet no signal is present in the BC region
performing the dilution in CDCl3 (see Fig. 4.13, red line).
Fig. 4.13: Absorption spectra of 5 µL of sol. X in 2 mL of stab-CDCl3 (blue line) and CDCl3 (red
line); absorption spectra of 30 µL of sol. X in 2 mL of CDCl3 (black-dotted line).
I add 5 µL at a time of sol. X to the latter BC solution: no BC absorption spectrum
has been observed until 30 µL of sol. X are added in the 2 mL (spectrum with black
dotted line in Fig. 4.13). According to this titration and hypothesizing that the
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stoichiometry of the reaction between impurities and BC is 1:1, I estimate that the
concentration of reacting impurities in CDCl3 is 0.045 mM, corresponding to 3.6
ppm.
Since it has been reported that trace amounts of HCl or free Cl dissolved in CDCl3 may
induced BC polymerization [10], I perform NMR analysis to understand whether
BC polymers are present. This measurement requires BC concentration higher
than those used in the previous experiments to obtain a good S/N ratio. Thus, I
concentrate a 45 µM BC solution in CDCl3 up to 2.5 mM and the acquired spectrum
is reported in Fig. 4.14. There is an evident peak broadening, suggesting that BC
oligomerization/polymerization is occurred.
Fig. 4.14: NMR spectra of BC in CDCl3.
BC dissolved in THF Similarly to the results presented in the above, I check the
effects that oxidant impurities in anhydrous THF have on BC degradation.
THF is known to contain peroxides species and to quantify their amount I prepare
a 0.01 M aqueous solution of KI, that I add to the same amount of both THF just
opened (THFnew) and opened few weeks before the analysis (THFold). The acquired
absorption spectra are reported in Fig. 4.15 (left panel). The relative amount of
peroxides in the solutions can be estimated from the ratio between the intensities
at 354 nm, since this peak is due to the I2 formed when I− reacts with the peroxides
and I find that the peroxides concentration in THFold is 5 times that in THFnew.
I dissolved BC (ε=144000 L·mol−1cm−1) in THFold and THFnew and I do not ob-
serve any variation in the BC absorbance within 24 h. Yet, when degraded-BC is
dissolved in THFnew, I note a decrease in absorbance within 24 h (as reported in
the right panel of Fig. 4.15). The facts that non-degraded BC does not change
its spectral characteristics, neither in THFold nor in THFold, while degraded BC is
further degraded even in THFnew suggest that the BC degradation in THF might
occur through radical reactions: once the process is started, it is quicker and possibly
catalysed by the peroxides present in solution.
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Fig. 4.15: Left panel reports the absorption spectra of THFnew (black line) and THFold (green line)
dissolved in 0.01 M aqueous solution of KI. Right panel shows the absorption spectra of
BC with ε=12000 L·mol−1cm−1 dissolved in THFnew at time t=0 (red continuous line)





UV-VIS analysis has been performed on a Varian CARY-100 UV-VIS Spectropho-
tometer, with spectral resolution of 1 nm; all the spectra have been acquired using
a quartz cuvette and baseline corrected against the same cuvette filled with the
solvent.
ζ-potential measurements have been performed on a Zetasizer Nano ZS instrument
(Malvern Instruments, Worcestershire, UK) equipped with a 633 nm He-Ne and a
universal dip cell (ZEN1002). The ζ-potential has been estimated by applying the
Smoluchowski model and by using refractive index and absorbance values of 2 and
0.2, respectively.
FTIR spectra have been acquired on a micro-FTIR Nicolet iN10 instrument equipped
with a liquid nitrogen cooled detector. 300 µm2 of the samples have been scanned
in %R mode in the range 700-4000 cm−1 with a 4 cm−1 spectral resolution.
RAMAN measurements have been performed on a LabRAM Aramis equipped with
a 532 nm laser and a 1800 lines/mm grating. Each spectrum has been acquired by
summing up 30 acquisitions, each one integrating the signal for 2 seconds.
HPLC analysis has been carried out on Agilent 1100 (Agilent Technologies, USA)
by injecting 10 µL of sample onto an RP-8 column (Agilent ZORBAX Eclipse XDB-C8)
and then detecting the eluted analytes with a photodiode array detector (Agilent
1220 Series, Agilent Technologies, Santa Clara, USA). Analytical separation has been
achieved by using a gradient program (constant flow 0.8 mL/min) starting with a
65:35 ratio of mobile phases A (70:30 CH3OH/H2O containing 12 mM ammonium
acetate) and B (CH3OH with12 mM ammonium acetate) that has been gradually
increased to 100% B over 40 min.
NMR measurements (NMR 1H, 400 MHz) have been recorded in stab-CDCl3 at 300
K on a Bruker Avance 400 MHz NMR spectrometer, using a 5 mm BBI probe with
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90◦ proton pulse length of 8.7 µs at a transmission power of 0 db and equipped
with pulsed gradient field utility. The chemical shift scale has been calibrated on
the residual proton signal of CDCl3 at 7.26 ppm.
MALDI-TOF analyisis has been performed in both positive and negative mode on a
MALDI-TOF/TOF 4800 AB Sciex, equipped with a Nd:YAG (355 nm) 200 Hz laser;
the extraction fields have been set at 20kV and the delay extraction fixed at 400
ns. Each spectrum is the accumulation of 1500 spectra acquired in 30 different
randomly selected spot areas.
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